[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1587
1. Segawa E, Hashitani S, Toyohara Y, Kishimoto H, Noguchi K, Takaoka K, Urade M: Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell line. Oncol Rep; 2009 Apr;21(4):869-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell line.
  • In order to investigate the involvement of cyclooxygenase (COX)-2 in oral carcinogenesis and chemoprevention for it, we examined the COX-2 expression during dimethylbenzanthracene (DMBA)-induced hamster cheek pouch carcinogenesis and the inhibitory effect of sulindac, a non-steroidal anti-inflammatory drug (NSAID), on the carcinogenesis and its derived squamous carcinoma cell line HCPC-1.
  • From the beginning of DMBA application, basal diet or diets containing sulindac 200 or 400 ppm were given to hamsters, and observation of tumor development and measurement of body weight were performed.
  • Immunohistochemical analysis revealed that COX-2 expression was increased toward carcinogenesis from epithelial dysplasia to squamous cell carcinoma (SCC).
  • All hamsters developed SCC, but the onset of carcinoma formation was significantly delayed up to 14.8 and 11.8 weeks in the 200 ppm, and 400 ppm sulindac group, respectively, as compared to 8.7 weeks in the control group.
  • In addition, tumor growth was retarded in the group of sulindac treatment, and mean survival time was 23.7 weeks in the control group and 36.3 and 33.8 weeks in the 200 and 400 ppm sulindac group, respectively.
  • Histologically, administration of sulindac inhibited angiogenesis in the tumor stroma.
  • Treatment with sulindac sulfide, an active metabolite of sulindac, caused inhibition of cell growth, PGE2 production and VEGF production in HCPC-1 cells in vitro.
  • It was thus indicated that inhibitory effects were partly due to inhibition of tumor angiogenesis by sulindac.
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cheek. Cricetinae. Cyclooxygenase 2 / analysis. Dinoprostone / biosynthesis. Male. Mesocricetus. Mouth Mucosa. Neovascularization, Pathologic / prevention & control. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287981.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Vascular Endothelial Growth Factor A; 184SNS8VUH / Sulindac; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 1.14.99.1 / Cyclooxygenase 2; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


2. Ly E, Piot O, Durlach A, Bernard P, Manfait M: Differential diagnosis of cutaneous carcinomas by infrared spectral micro-imaging combined with pattern recognition. Analyst; 2009 Jun;134(6):1208-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of cutaneous carcinomas by infrared spectral micro-imaging combined with pattern recognition.
  • Non-melanoma skin cancer includes basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and Bowen's disease.
  • The differential diagnosis of these lesions is sometimes difficult and relies on the histopathological examination of surgical specimens.
  • However, a precise differential diagnosis is crucial for an accurate therapy and thus better patient care.
  • FTIR spectral micro-imaging was applied directly on formalin-fixed paraffin-embedded samples of non-melanoma skin cancers.
  • High correlation was obtained between the prediction maps and the histology which proves the great potential of FTIR spectroscopy for the differential diagnosis of skin carcinomas.
  • [MeSH-major] Pattern Recognition, Automated. Skin Neoplasms / diagnosis
  • [MeSH-minor] Algorithms. Diagnosis, Differential. Discriminant Analysis. Eccrine Glands / pathology. Hair Follicle / pathology. Humans. Image Interpretation, Computer-Assisted. Principal Component Analysis. Reproducibility of Results. Sebaceous Glands / pathology. Spectroscopy, Fourier Transform Infrared

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475150.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


3. Han J, Colditz GA, Hunter DJ: Lack of associations of selected variants in genes involved in cell cycle and apoptosis with skin cancer risk. Cancer Epidemiol Biomarkers Prev; 2006 Mar;15(3):592-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of associations of selected variants in genes involved in cell cycle and apoptosis with skin cancer risk.
  • [MeSH-major] Caspases / genetics. Cyclin D1 / genetics. Genetic Variation. Polymorphism, Genetic. Skin Neoplasms / epidemiology. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Apoptosis / genetics. Biopsy, Needle. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Cell Cycle / genetics. Confidence Intervals. Female. Gene Expression Regulation, Neoplastic. Humans. Incidence. Melanoma / epidemiology. Melanoma / genetics. Melanoma / pathology. Middle Aged. Multivariate Analysis. Odds Ratio. Probability. Prognosis. Reference Values. Risk Assessment. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537723.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA113100; United States / NCI NIH HHS / CA / CA87969
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1; EC 3.4.22.- / Caspases
  •  go-up   go-down


Advertisement
4. Hafner C, Becker B, Landthaler M, Vogt T: Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol; 2006 Oct;19(10):1369-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer.
  • However, the Eph/ephrin expression profile in human skin is only marginally studied.
  • We therefore investigated the mRNA expression of 21 Eph receptors and ephrin ligands in adult human skin in comparison to 13 other adult human tissues using quantitative real-time RT-PCR.
  • In addition, immunohistochemistry was established for some members (EphA1, EphA2 and EphA7) to confirm the results of the RT-PCR and to identify the expressing cells in the skin.
  • We found all investigated family members expressed in human skin, but at highly varying levels.
  • EphA1, EphB3 and ephrin-A3 turned out to be most prominently expressed in skin compared to other adult human tissues.
  • We therefore investigated the expression of EphA1 in nonmelanoma skin cancers derived from the epidermis (56 basal cell carcinomas and 32 squamous cell carcinomas).
  • As demonstrated by immunohistochemistry, both skin cancers displayed a significant downregulation of EphA1 compared to the normal epidermis.
  • In squamous cell carcinoma, the EphA1 downregulation was associated with increased tumor thickness, although this was not significant.
  • Our results indicate that Eph receptors and ephrin ligands are widely expressed in the adult human skin, particularly in the epidermis, and may play an important role in skin homeostasis.
  • EphA1 seems to be a marker of the differentiated normal epidermis and its downregulation in nonmelanoma skin cancer may contribute to carcinogenesis of these very frequent human tumors.
  • EphA1 represents a new potential prognostic marker and therapeutic target in nonmelanoma skin cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Ephrins / analysis. Neoplasms, Basal Cell / chemistry. Receptor, EphA1 / analysis. Skin / chemistry. Skin Neoplasms / chemistry. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Down-Regulation. Ephrin-A3 / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. RNA, Messenger / metabolism. Receptor, EphB3 / analysis. Reverse Transcriptase Polymerase Chain Reaction. Skin Ulcer / metabolism. Skin Ulcer / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16862074.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ephrin-A3; 0 / Ephrins; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, EphA1; EC 2.7.10.1 / Receptor, EphB3
  •  go-up   go-down


5. Nicolae I, Schipor S: PTH-independent hypercalcaemia and non-melanoma skin cancer. J Eur Acad Dermatol Venereol; 2010 Apr;24(4):449-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTH-independent hypercalcaemia and non-melanoma skin cancer.
  • BACKGROUND: Recently, it became more evident that skin is a target for neuroendocrine signals. AIMS:.
  • (1) To evaluate the relationship between tumour aggressiveness and hypercalcaemia in patients with non-melanoma skin cancer;.
  • From the 1232 cases that were investigated, there were 32 patients with keratoachantoma, 468 patients with basal cell carcinoma, 412 patients with squamous cell carcinoma and 320 healthy volunteers.
  • In tumour tissues and intact skin, calcium was assayed by physical methods of analysis: Instrumental Neutron Activation Analysis (INAA), Proton-Induced X-ray Emission (PIXE).
  • A possible mechanism is PTHrp hypersecretion by malignant keratinocytes.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Hypercalcemia / epidemiology. Keratoacanthoma / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Calcium / blood. Calcium / urine. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / metabolism. Extracellular Fluid / metabolism. Female. Humans. Male. Middle Aged. Models, Biological. Parathyroid Hormone / metabolism. Prevalence. Romania / epidemiology. Serum Albumin / metabolism. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778357.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Serum Albumin; SY7Q814VUP / Calcium
  •  go-up   go-down


6. An JY, Fan ZM, Gao SS, Zhuang ZH, Qin YR, Li JL, He X, Tsao GS, Wang LD: Loss of heterozygosity in multistage carcinogenesis of esophageal carcinoma at high-incidence area in Henan Province, China. World J Gastroenterol; 2005 Apr 14;11(14):2055-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity in multistage carcinogenesis of esophageal carcinoma at high-incidence area in Henan Province, China.
  • The rate of LOH increased remarkably with the lesions progressed from basal cell hyperplasia (BCH) to squamous cell carcinoma (SCC) (P<0.05).

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15810068.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA065871; United States / NCI NIH HHS / CA / CA65871
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4305771
  •  go-up   go-down


7. Konstantinović VS, Lazić VM, Stefan I: Nasal epithesis retained by basal (disk) implants. J Craniofac Surg; 2010 Jan;21(1):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal epithesis retained by basal (disk) implants.
  • AIM: To report the case of a patient who underwent facial reconstruction with nasal epithesis anchored on basal (disk) implants after ablation of midface squamous cell carcinoma.
  • METHODS: Ablative surgery of the midface region and insertion of 3 basal implants into the glabellar area of the frontal bone, the upper part of the right side of the alveolar crest, and the lateral side of the maxillary bone, which forms the left lateral wall of the nose, respectively, was performed.
  • At the control examinations after 1, 3, 6, 12, and 18 months, respectively, there were no signs of recurrence of the tumor or any complications related to the implants.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Facial Bones / surgery. Facial Neoplasms / surgery. Nose Neoplasms / surgery. Prostheses and Implants. Skull Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061980.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Nindl I, Gottschling M, Stockfleth E: Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers; 2007;23(4):247-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations.
  • Human papillomaviruses (HPV) infect cutaneous and mucosal epithelia and induce benign and malignant lesions.
  • Non-melanoma skin cancer (NMSC), encompassing basal cell carcinoma and squamous cell carcinoma (SCC), is the most frequent cancer in the Caucasian population, and the incidence has increased dramatically worldwide.
  • HPV types detected in skin tumours of these patients are referred to as EV/cutaneous HPV types belonging to the beta- and gamma-papillomaviruses (PV).
  • [MeSH-major] Papillomaviridae / pathogenicity. Papillomavirus Infections / complications. Skin Neoplasms / etiology
  • [MeSH-minor] Animals. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / virology. Disease Models, Animal. Epidermodysplasia Verruciformis / complications. Epidermodysplasia Verruciformis / virology. Humans. Immune Tolerance. Risk Factors. Transplantation Immunology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627060.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 155
  • [Other-IDs] NLM/ PMC3851066
  •  go-up   go-down


9. Veness MJ, Harris D: Role of radiotherapy in the management of organ transplant recipients diagnosed with non-melanoma skin cancers. Australas Radiol; 2007 Feb;51(1):12-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of radiotherapy in the management of organ transplant recipients diagnosed with non-melanoma skin cancers.
  • Non-melanoma skin cancer (NMSC) is the most common malignancy worldwide, arising most often on the sun-exposed head and neck.
  • Organ transplant recipients experience a higher incidence of NMSC when compared with the general population and a higher incidence of squamous cell carcinoma compared with basal cell carcinoma.
  • Radiation oncologists treating patients with skin cancer will almost certainly make recommendations in the setting of NMSC arising in OTR.
  • The emphasis will be on the treatment of patients with a high-risk NMSC (e.g. squamous cell carcinoma, Merkel cell carcinoma, unfavourable basal cell carcinoma) because this reflects the most common clinical scenario in which a recommendation of radiotherapy, usually adjuvant, may be considered.
  • [MeSH-major] Organ Transplantation. Skin Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17217484.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 44
  •  go-up   go-down


10. Yaroslavsky AN, Barbosa J, Neel V, DiMarzio C, Anderson RR: Combining multispectral polarized light imaging and confocal microscopy for localization of nonmelanoma skin cancer. J Biomed Opt; 2005 Jan-Feb;10(1):14011
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining multispectral polarized light imaging and confocal microscopy for localization of nonmelanoma skin cancer.
  • Multispectral polarized light imaging (MSPLI) enables rapid inspection of a superficial tissue layer over large surfaces, but does not provide information on cellular microstructure.
  • In practice, pathologists use microscopes at low and high power to view tumor margins and cell features, respectively.
  • Therefore, we study the combination of CM and MSPLI for demarcation of nonmelanoma skin cancers.
  • Freshly excised thick skin samples with nonmelanoma cancers are rapidly stained with either toluidine or methylene blue dyes, rinsed in acetic acid, and imaged using MSPLI and CM.
  • Cytological features are identified by CM, and tumor margins are delineated by MSPLI.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Microscopy, Confocal. Microscopy, Polarization. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Society of Photo-Optical Instrumentation Engineers
  • (PMID = 15847592.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB002423-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 15XUH0X66N / Tolonium Chloride; T42P99266K / Methylene Blue
  •  go-up   go-down


11. Sprecher E: Genetic factors in the pathogenesis of UV-induced skin cancer1. Curr Probl Dermatol; 2007;35:28-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic factors in the pathogenesis of UV-induced skin cancer1.
  • UV light exposure has been incriminated for the steady rise in skin cancer incidence observed during the last years.
  • This review examines major progress in our understanding of major hereditary and nonhereditary genetic modifiers involved in the pathogenesis of UV-induced skin cancer.
  • [MeSH-major] Genetic Predisposition to Disease. Skin Neoplasms / etiology. Skin Neoplasms / genetics. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / genetics. Humans. Melanoma / etiology. Melanoma / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641488.001).
  • [ISSN] 1421-5721
  • [Journal-full-title] Current problems in dermatology
  • [ISO-abbreviation] Curr. Probl. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 83
  •  go-up   go-down


12. Lalli A, Tilakaratne WM, Ariyawardana A, Fitchett C, Leigh IM, Hagi-Pavli E, Cruchley AT, Parkinson EK, Teh MT, Fortune F, Waseem A: An altered keratinocyte phenotype in oral submucous fibrosis: correlation of keratin K17 expression with disease severity. J Oral Pathol Med; 2008 Apr;37(4):211-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An altered keratinocyte phenotype in oral submucous fibrosis: correlation of keratin K17 expression with disease severity.
  • Its influence on the overlying epithelium is not known but about 14% of OSF cases undergo malignant transformation to squamous cell carcinoma indicating association with abnormality of the epithelium.
  • We observed an increase of K1 and K10 in the suprabasal layers, induction of K6 in the basal layer and complete loss of K19 in the epithelium.
  • Furthermore, there was increased K17 expression in the suprabasal layers, which correlated with disease severity.
  • In a subset of the most severe OSF cases (14%), K17 expression was completely lost in the basal layer which might define them to be at most risk to undergo malignant transformation.
  • We propose that the altered keratin profiles could be useful as histological diagnostic markers and provide important insights into the pathogenesis of the disease and its predisposition to malignancy.
  • [MeSH-minor] Biomarkers. Carcinoma, Squamous Cell. Case-Control Studies. Cell Transformation, Neoplastic. Gene Expression. Humans. Immunohistochemistry. Keratin-17 / biosynthesis. Mouth Neoplasms / chemistry. Mouth Neoplasms / pathology. Phenotype. Photography, Dental. Precancerous Conditions / chemistry. Precancerous Conditions / pathology. Severity of Illness Index

  • Genetic Alliance. consumer health - Oral submucous fibrosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18205743.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Keratin-17; 68238-35-7 / Keratins
  •  go-up   go-down


13. Bashir M, Kirmani D, Bhat HF, Baba RA, Hamza R, Naqash S, Wani NA, Andrabi KI, Zargar MA, Khanday FA: P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers. Cell Commun Signal; 2010;8:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Members of Shc (src homology and collagen homology) family, p46shc, p52shc, p66shc have known to be related to cell proliferation and carcinogenesis.
  • In the present study, the expression of p66shc and its associate targets namely Eps8 (epidermal pathway substrate 8), Rac1 (ras-related C3 botulinum toxin substrate1) and Grb2 (growth factor receptor bound protein 2) were examined in fresh tissue specimens from patients with esophageal squamous cell carcinoma and esophageal adenocarcinoma using western blot analysis.
  • A thorough analysis of both esophageal squamous cell carcinoma and adenocarcinoma showed p66shc expression to be significantly higher in both types of carcinomas as compared to the controls.
  • The controls of adenocarcinoma show a higher basal expression level of p66shc as compared to the controls of squamous cell carcinoma.
  • The expression level of downstream targets of p66shc i.e., eps8 and rac1 was also found to be consistently higher in human esophageal carcinomas, and hence correlated positively with p66shc expression.
  • However the expression of grb2 was found to be equal in both esophageal squamous cell carcinoma and adenocarcinoma.
  • From the results it is also suggestive that p66shc may have a role in the regulation of esophageal carcinomas and represents a possible mechanism of signaling for the development of squamous cell carcinoma and adenocarcinoma of esophagus.


14. Warshauer E, Warshauer BL: Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy. J Drugs Dermatol; 2008 May;7(5):447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy.
  • The short-term and long-term outcomes of 108 patients with 122 nodular basal cell carcinomas (BCCs), morpheaform BCCs, or low-risk squamous cell carcinomas (SCCs) treated with imiquimod 5% cream at a community-based dermatology practice were retrospectively reviewed.
  • The overall initial tumor clinical cure rate was 93.4% (114/122), with an initial clinical cure rate of 90% (72/80) for BCCs combined, and 100% (42/42) for SCCs combined.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505136.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


15. Paradela S, Pita-Fernández S, Peña C, Fernández-Jorge B, García-Silva J, Mazaira M, Fonseca E: Complications of ambulatory major dermatological surgery in patients older than 85 years. J Eur Acad Dermatol Venereol; 2010 Oct;24(10):1207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: During the last decades, the progressive ageing of the population has resulted in a rising skin cancer incidence.
  • Studied variables were age, gender, tobacco-alcohol exposure, co-morbid medical conditions, blood-thinning medication, antibiotic prophylaxis, number of lesions, location, histopathological diagnosis, area of skin removed, surgical technique, type of flap, length of surgery, entrance order, suture thread, surgical complications and need of post-operative admission.
  • The most frequent tumour was basal cell carcinoma (45.1%), followed by squamous cell carcinoma (38.7%) and melanoma (8.3%).
  • Length of surgical procedure, area of skin removed and reconstruction with skin-graft were significantly related to higher risk of post-operative complications.
  • [MeSH-major] Ambulatory Surgical Procedures / adverse effects. Dermatologic Surgical Procedures. Skin / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Cellulitis / etiology. Cellulitis / pathology. Female. Humans. Male. Melanoma / surgery. Necrosis / etiology. Necrosis / pathology. Retrospective Studies. Spain. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal of the European Academy of Dermatology and Venereology © 2010 European Academy of Dermatology and Venereology.
  • (PMID = 20337810.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Leibovitch I, Huilgol SC, Hsuan JD, Selva D: Incidence of host site complications in periocular full thickness skin grafts. Br J Ophthalmol; 2005 Feb;89(2):219-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of host site complications in periocular full thickness skin grafts.
  • AIM: To evaluate the complications of periocular full thickness skin grafts (FTSG) in patients treated with Mohs' micrographic surgery (MMS) for periocular malignancy.
  • METHOD: This prospective, multicentre case series included all patients in Australia treated with MMS for periocular malignancy followed by reconstruction with FTSG, who were monitored by the Skin and Cancer Foundation, between 1993 and 1999.
  • 92.7% were diagnosed with basal call carcinoma, 2.0% with Bowen's disease, and 3.3% with squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Eyelid Neoplasms / surgery. Mohs Surgery. Skin Transplantation / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bowen's Disease / pathology. Bowen's Disease / surgery. Eyelids / pathology. Female. Humans. Hypertrophy / pathology. Male. Middle Aged. Prospective Studies. Regression Analysis. Skin / pathology. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Clin. 2000 Jul;18(3):521-32 [10943546.001]
  • [Cites] Br J Plast Surg. 2000 Jul;53(5):397-402 [10876276.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Aug;34(4):767-80, vi [11511475.001]
  • [Cites] Dermatol Surg. 2003 Jan;29(1):25-9 [12534508.001]
  • [Cites] Surg Gynecol Obstet. 1976 Jan;142(1):49-56 [1105840.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):151-65 [1430351.001]
  • [Cites] Surg Clin North Am. 1997 Jun;77(3):701-30 [9194888.001]
  • [Cites] Dermatol Clin. 1998 Jan;16(1):75-90 [9460579.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1998 Sep;14(5):352-9 [9783288.001]
  • [Cites] Plast Reconstr Surg (1946). 1951 Nov;8(5):378-89 [14891384.001]
  • [Cites] Br J Plast Surg. 1956 Oct;9(3):212-21 [13374260.001]
  • [Cites] Ann Plast Surg. 1991 Apr;26(4):347-52 [1872540.001]
  • (PMID = 15665356.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1772525
  •  go-up   go-down


17. Schmerber S, Righini Ch, Soriano E, Delalande C, Dumas G, Reyt E, Lavieille JP: [The outcome of treatments for carcinoma of the external auditory canal]. Rev Laryngol Otol Rhinol (Bord); 2005;126(3):165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The outcome of treatments for carcinoma of the external auditory canal].
  • OBJECTIVE: A retrospective analysis of management and survival of patients treated for temporal bone carcinoma.
  • PATIENTS AND METHODS: Thirty patients underwent treatment for carcinoma of the temporal bone.
  • Twenty-five squamous cell carcinomas, 1 melanoma, 2 basocellular carcinomas and 2 adenoid cystic carcinomas were treated.
  • Thirteen patients were treated before for the same disease.
  • CONCLUSION: Long-term prognosis of the carcinoma of the external auditory canal mainly depends on the stage and primary treatment.
  • Surgery (lateral temporal bone or subtotal temporal bone resection, both in combination with a neck dissection and a parotidectomy) and adjuvant radiotherapy is the treatment of choice for part of stage T1 and all T2 and T3 tumours.
  • The improved survival (65%) of patients treated de novo compared with those treated with salvage surgery (23%) suggests that early referral and aggressive primary surgical treatment with postoperative radiotherapy offer the greatest chance of cure.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Ear Canal. Ear Neoplasms / therapy. Ear, Middle. Melanoma / therapy. Skull Neoplasms / therapy. Temporal Bone
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Parotid Gland / surgery. Petrous Bone / surgery. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366384.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Arad S, Zattra E, Hebert J, Epstein EH Jr, Goukassian DA, Gilchrest BA: Topical thymidine dinucleotide treatment reduces development of ultraviolet-induced basal cell carcinoma in Ptch-1+/- mice. Am J Pathol; 2008 May;172(5):1248-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical thymidine dinucleotide treatment reduces development of ultraviolet-induced basal cell carcinoma in Ptch-1+/- mice.
  • Treatment with thymidine dinucleotide (pTT) has well documented DNA-protective effects and reduces development of squamous cell carcinoma in UV-irradiated mice.
  • The preventive effect of pTT on basal cell carcinoma (BCC) was evaluated in UV-irradiated Ptch-1(+/-) mice, a model of the human disease Gorlin syndrome.
  • Topical pTT treatment significantly reduced the number and size (P < 0.001) of BCCs in murine skin after 7 months of chronic irradiation.
  • Skin biopsies collected 24 hours after the final UV exposure showed that pTT reduced the number of nuclei positive for cyclobutane pyrimidine dimers by 40% (P < 0.0002) and for 8-hydroxy-2'-deoxyguanosine by 61% (P < 0.01 compared with vehicle control).
  • Immunostaining with an antibody specific for mutated p53 revealed 63% fewer positive patches in BCCs of pTT-treated mice compared with controls (P < 0.01), and the number of Ki-67-positive cells was decreased by 56% (P < 0.01) in pTT-treated tumor-free epidermis and by 76% (P < 0.001) in BCC tumor nests (P < 0.001).
  • Cox-2 immunostaining was decreased by 80% in tumor-free epidermis of pTT-treated mice compared with controls (P < 0.01).

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Feb 2;280(4):1042-7 [11162632.001]
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):293-7 [11174390.001]
  • [Cites] EMBO J. 2001 Oct 1;20(19):5532-40 [11574485.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] FASEB J. 2002 May;16(7):754-6 [11923222.001]
  • [Cites] Photochem Photobiol. 2002 Jul;76(1):73-80 [12126310.001]
  • [Cites] Australas J Dermatol. 2002 Nov;43(4):241-6 [12423429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):527-31 [12515865.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):934-41 [14871823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3933-8 [14999099.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4385-9 [15231643.001]
  • [Cites] FASEB J. 2004 Sep;18(12):1373-81 [15333580.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7545-52 [15492281.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1614-8 [8434025.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4756-9 [8062275.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):413-4 [7984233.001]
  • [Cites] Science. 1994 Dec 23;266(5193):1954-6 [7801120.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):274-8 [8552621.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1087-92 [8577719.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 20;88(6):349-54 [8609643.001]
  • [Cites] J Invest Dermatol. 1996 Nov;107(5):733-7 [8875958.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12627-32 [9356500.001]
  • [Cites] Nat Med. 1998 May;4(5):619-22 [9585239.001]
  • [Cites] J Invest Dermatol. 1999 Jan;112(1):25-31 [9886259.001]
  • [Cites] Science. 1999 Feb 26;283(5406):1321-5 [10037601.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):10911-5 [10196169.001]
  • [Cites] Cell. 1999 May 14;97(4):503-14 [10338214.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1939-44 [10506108.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2006-11 [15598755.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):43-51 [15656799.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 Mar;19(2):180-6 [15752287.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6006-10 [16024598.001]
  • [Cites] J Biol Chem. 2005 Sep 16;280(37):32379-88 [16046401.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Nov;10(2):124-30 [16363064.001]
  • [Cites] J Invest Dermatol. 2006 May;126(5):1143-51 [16528365.001]
  • [Cites] Prog Biophys Mol Biol. 2006 Sep;92(1):92-6 [16616325.001]
  • [Cites] FASEB J. 2006 Sep;20(11):1895-7 [16877521.001]
  • [Cites] J Cell Physiol. 2007 Mar;210(3):582-95 [17133364.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):435-40 [10951280.001]
  • [Cites] DNA Repair (Amst). 2007 Apr 1;6(4):544-59 [17112792.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R13 [17257427.001]
  • [Cites] FASEB J. 2007 Sep;21(11):2918-30 [17449721.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Nov 1;224(3):257-64 [17276471.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • (PMID = 18403589.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 10515; United States / NCI NIH HHS / CA / R01 CA109584; United States / NIAMS NIH HHS / AR / AR 050440; United States / NIAMS NIH HHS / AR / P01 AR050440; United States / NCI NIH HHS / CA / CA 109584
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Pyrimidine Dimers; 0 / Receptors, Cell Surface; 0 / Thymine Nucleotides; 0 / patched receptors; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  • [Other-IDs] NLM/ PMC2329834
  •  go-up   go-down


19. Adegboyega PA, Boromound N, Freeman DH: Diagnostic utility of cell cycle and apoptosis regulatory proteins in verrucous squamous carcinoma. Appl Immunohistochem Mol Morphol; 2005 Jun;13(2):171-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of cell cycle and apoptosis regulatory proteins in verrucous squamous carcinoma.
  • A major problem in the diagnosis of verrucous squamous cell carcinoma is the lack of readily reproducible objective criteria for distinguishing this malignant lesion from reactive epithelial hyperplasia.
  • Both lesions are characterized by thickened (well-differentiated) squamous epithelium without cellular atypia and subjacent stroma densely infiltrated by lymphocytes and plasma cells.
  • This study was carried out to evaluate the use of cell cycle and apoptosis-related regulatory proteins in the diagnosis of verrucous carcinoma.
  • The study materials consisted of representative formalin-fixed and paraffin-embedded tissue blocks from 19 cases of verrucous carcinoma, 18 classic squamous cell carcinoma, and 14 squamous epithelial hyperplasia (acanthosis).
  • The immunohistochemical expression of the following of cell cycle and apoptosis-related regulatory proteins was evaluated using avidin-biotin complex detection technique: p16, p21, p53, Ki67, and retinoblastoma gene product (RBGP) (also known as retinoblastoma protein [pRb]).
  • Expression of Ki67 was detected only in the single basal layer of the epithelium in all 14 cases of acanthosis.
  • In verrucous carcinoma, Ki67 was detected in basal and suprabasal cells in the lower third of the neoplastic epithelium in 19 of 19 cases (100%).
  • In neoplastic squamous epithelium with frankly invasive squamous cell carcinoma, Ki67 was diffusely expressed throughout the entire thickness of the epithelium as well as in the underlying invasive tumor nests.
  • In addition, immunohistochemical expression of p53 in the hyperplastic squamous epithelium was very weak, in contrast to the more intense immunoreactivity observed in verrucous carcinoma and classic squamous cell carcinoma.
  • We therefore conclude that the pattern of Ki67 and p53 expression in verrucous carcinoma is readily reproducible and distinctly different from that observed in epithelial hyperplasia and that seen in invasive squamous cell carcinoma.
  • Thus Ki67, and p53 immunostains are reliable adjuncts that may be helpful in resolving diagnostic problems associated with verrucous carcinoma.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894931.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


20. Burstein DE, Nagi C, Kohtz DS, Lee L, Wang B: Immunodetection of GLUT1, p63 and phospho-histone H1 in invasive head and neck squamous carcinoma: correlation of immunohistochemical staining patterns with keratinization. Histopathology; 2006 May;48(6):717-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunodetection of GLUT1, p63 and phospho-histone H1 in invasive head and neck squamous carcinoma: correlation of immunohistochemical staining patterns with keratinization.
  • Immunodetection of GLUT1, p63 and phospho-histone H1 in invasive head and neck squamous carcinoma: correlation of immunohistochemical staining patterns with keratinizationAims : To examine invasive head and neck squamous carcinomas for expression of GLUT1, a glucose transporter and marker of increased glucose uptake, glycolytic metabolism and response to tissue hypoxia; p63, a p53 homologue that is a marker of the undifferentiated proliferative basaloid phenotype; and phospho-histone H1, a marker of activation of the cell cycle-promoting cyclin-dependent kinases 1 and 2.
  • Methods : Routinely processed slides from 34 invasive squamous carcinomas, including 25 with intraepithelial components, were immunostained with anti-GLUT1 (Chemicon), anti-p63 (4A4, Santa Cruz), and antiphospho-histone H1 (monoclonal 12D11).
  • Results : In keratinizing carcinomas, all three markers were most commonly immunodetected peripherally, with loss of expression in central keratinized zones.
  • In contrast, in non-keratinizing carcinomas, p63 and phospho-histone H1 expression was most commonly observed throughout tumour nests and anti-GLUT1 stained in a pattern suggestive of hypoxia-induced expression ('antistromal' staining), in which cells at the tumour-stromal interface were GLUT1- and cells in central, perinecrotic zones showed progressive induction of GLUT1.
  • Intraepithelial components also displayed basal and 'antibasal' GLUT1 staining patterns, homologous to the pro- and antistromal patterns in invasive carcinoma; basal patterns in intraepithelial lesions appeared to be more predictive of keratinizing invasive carcinoma and antibasal intraepithelial staining more predictive of non-keratinizing poorly differentiated carcinomas.
  • Conclusions : Keratinizing and non-keratinizing squamous carcinomas differ in expression patterns of GLUT1, p63 and phospho-histone H1.
  • GLUT1 expression patterns in intraepithelial lesions may be predictive of the differentiation status of the associated invasive carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology
  • [MeSH-minor] DNA-Binding Proteins / analysis. Disease Progression. Glucose Transporter Type 1 / analysis. Histones / analysis. Histones / metabolism. Humans. Immunohistochemistry. Keratins / metabolism. Neoplasm Invasiveness. Phosphoproteins / analysis. Phosphorylation. Trans-Activators / analysis. Transcription Factors. Tumor Suppressor Proteins / analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681688.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Glucose Transporter Type 1; 0 / Histones; 0 / Phosphoproteins; 0 / SLC2A1 protein, human; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


21. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther; 2010 Nov-Dec;23(6):651-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach.
  • Electroporation uses pulsed, high-intensity electric fields to temporarily increase cell membrane permeability by creation of pores, through which small molecules, such as chemotherapeutic agents, can diffuse inside cells before they reseal.
  • ECT has already been proven to be effective in diverse tumor histotypes, including melanoma and basal and squamous cell carcinoma, Kaposi sarcoma, and breast cancer, also in those cases nonresponding to classical chemotherapies or other loco-regional treatment modalities, with a good safety profile.
  • ECT can be proposed as loco-regional therapy for disseminated cutaneous and subcutaneous tumor lesions as alternative treatment modality to conventional therapies or as palliative care, in order to improve patients' quality of life.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Electrochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Humans. Skin / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley Periodicals, Inc.
  • (PMID = 21054709.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Granger RH, Blizzard L, Fryer JL, Dwyer T: Association between dietary fat and skin cancer in an Australian population using case-control and cohort study designs. BMC Cancer; 2006;6:141
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between dietary fat and skin cancer in an Australian population using case-control and cohort study designs.
  • BACKGROUND: Human studies of dietary fat as a possible risk factor for cutaneous malignant melanoma (CMM) and non-melanoma skin cancer (NMSC)--principally basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)--have produced inconsistent results.
  • We had the opportunity to examine the association concurrently for all three types of skin cancer in a population-based study in Tasmania, Australia, involving 652 cases of CMM, BCC and SCC and a common set of 471 controls.
  • METHODS: Histopathologically-confirmed cases of CMM, BCC and SCC were ascertained from the Tasmanian Cancer Registry (TCR), and controls were selected at random from the state's electoral roll.
  • We compared subjects categorised by thirds of dietary fat intake score measured by the 'Dobson short fat questionnaire', with logistic regression models that adjusted for age, sex, skin type and usual sun exposure.
  • CONCLUSION: Using the same dietary instrument with two study designs in the same Caucasian population, we found no evidence that high fat intake increases the risk of developing melanoma or non-melanoma skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Dietary Fats / administration & dosage. Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1983 May;43(5 Suppl):2409s-2413s [6831465.001]
  • [Cites] Med J Aust. 1980 Feb 23;1(4):159-63 [7374545.001]
  • [Cites] Recent Results Cancer Res. 1986;102:38-55 [3738186.001]
  • [Cites] Int J Cancer. 1988 Aug 15;42(2):200-6 [3403065.001]
  • [Cites] Am J Epidemiol. 1990 Apr;131(4):597-611 [2316493.001]
  • [Cites] Photochem Photobiol. 1992 Aug;56(2):195-9 [1502263.001]
  • [Cites] Aust J Public Health. 1993 Jun;17(2):144-9 [8399708.001]
  • [Cites] Ann Epidemiol. 1992 May;2(3):231-9 [1342273.001]
  • [Cites] Ann Epidemiol. 1993 May;3(3):235-8 [8275194.001]
  • [Cites] Am J Epidemiol. 1994 May 1;139(9):869-80 [8166137.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):165-9 [7622291.001]
  • [Cites] Int J Dermatol. 1995 Jun;34(6):398-402 [7657438.001]
  • [Cites] Nutr Cancer. 1997;27(2):150-6 [9121942.001]
  • [Cites] Int J Cancer. 1997 May 16;71(4):600-4 [9178814.001]
  • [Cites] Mutat Res. 1998 Nov 9;422(1):185-90 [9920444.001]
  • [Cites] Drugs Today (Barc). 2005 Jan;41(1):37-53 [15753968.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1596-607 [16030089.001]
  • [Cites] Am J Clin Nutr. 2000 Jan;71(1):135-41 [10617958.001]
  • [Cites] Nutr Cancer. 2000;36(2):155-62 [10890025.001]
  • [Cites] Am J Epidemiol. 2002 Apr 1;155(7):614-21 [11914188.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):1017-22 [12072070.001]
  • [Cites] Lancet. 2003 Jul 19;362(9379):212-4 [12885485.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1042-51 [15184262.001]
  • [Cites] Am J Epidemiol. 1986 Jul;124(1):17-27 [3521261.001]
  • (PMID = 16734890.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats
  • [Other-IDs] NLM/ PMC1481578
  •  go-up   go-down


23. Utikal J, Udart M, Leiter U, Kaskel P, Peter RU, Krähn G: Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer. Cancer Lett; 2005 Mar 10;219(2):197-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer.
  • Deregulation of the cell-cycle G1-restriction point control via abnormalities of Rb-pathway components is a frequent event in the formation of cancer.
  • The aim of this study was to evaluate numerical aberrations of the Cyclin D1 (CCND1, PRAD1, bcl-1) gene locus at chromosome 11q13 in basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) of the skin and to compare it with the Cyclin D1 protein expression.
  • All SCCs and the BCC with additional Cyclin D1 gene copies showed positivity for Cyclin D1 protein.
  • Our findings suggest that numerical abnormalities of the Cyclin D1 gene locus could result in an altered gene-dose effect, possibly leading to an aberrant expression in affected tumor cells.
  • This might result in deregulation of cell cycle control, eventually leading to uncontrolled cell cycle progression.
  • [MeSH-major] Aneuploidy. Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Chromosomes, Human, Pair 11. Cyclin D1 / genetics. Cyclin D1 / metabolism. Skin Neoplasms / genetics


24. Tan E, Oakley A, Soyer HP, Haskett M, Marghoob A, Jameson M, Rademaker M: Interobserver variability of teledermoscopy: an international study. Br J Dermatol; 2010 Dec;163(6):1276-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Teledermoscopy is a rapidly developing field of dermatology with studies demonstrating excellent agreement with face-to-face diagnosis.
  • However, we are unaware of studies evaluating interobserver variability in diagnosis between dermatologists from different continents.
  • RESULTS: There was excellent agreement between four of five dermatologists (A-D) for lesions that were agreed upon as melanoma (κ = 0·81-0·97) and benign naevus (κ = 0·77-0·82).The fifth dermatologist (E) made a more frequent diagnosis of atypical naevus and melanoma than the others.
  • For nonmelanocytic lesions, there was moderate to very good agreement for seborrhoeic keratosis (κ = 0·64-0·80) and basal cell carcinoma (κ = 0·55-0·67), but poor agreement for invasive squamous cell carcinoma (SCC) (κ = 0·05-0·15).
  • There was good ability to distinguish malignant from benign lesions (κ = 0·57-0·93).
  • CONCLUSIONS: There was good agreement among dermatologists A-D but dermatologist E varied from the group with more frequent diagnosis of melanoma and atypical naevus.
  • [MeSH-major] Dermoscopy / methods. Remote Consultation / standards. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 20795998.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. van den Top JG, de Heer N, Klein WR, Ensink JM: Penile and preputial tumours in the horse: a retrospective study of 114 affected horses. Equine Vet J; 2008 Sep;40(6):528-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data recorded included age, gelding or stallion and breed; type and site of lesion; involvement of regional lymph nodes; histopathology (including grading of squamous cell carcinoma); and results of radiographic examination of the thorax.
  • Common presenting clinical signs were irregularities (e.g. the presence of a mass and/or ulceration) on the integument of the penis and prepuce, and purulent or sanguineous discharge from preputial orifice.
  • Squamous cell carcinoma (SCC) was the most prevalent neoplasm followed by papillomas and melanomas.
  • A basal cell carcinoma, neurofibrosarcoma, adenocarcinoma or fibrosarcoma were each found on single horses.
  • Squamous cell carcinomas with poor differentiation had a higher tendency to metastasise than did more differentiated tumours.
  • CONCLUSIONS: Squamous cell carcinoma is the most common urogenital tumour of the male horse and occurs primarily in old horses.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Horse Diseases / pathology. Penile Neoplasms / veterinary
  • [MeSH-minor] Age Factors. Animals. Breeding. Horses. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis / diagnosis. Male. Neoplasm Metastasis / diagnosis. Neoplasm Staging / veterinary. Orchiectomy / veterinary. Papilloma / epidemiology. Papilloma / pathology. Papilloma / surgery. Papilloma / veterinary. Pedigree. Penis / pathology. Penis / surgery. Retrospective Studies. Urethra / pathology. Urethra / surgery

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487101.001).
  • [ISSN] 0425-1644
  • [Journal-full-title] Equine veterinary journal
  • [ISO-abbreviation] Equine Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. González-Guerra E, Requena L, Kutzner H: [Immunohistochemical study of calretinin in normal hair follicles and tumors with follicular differentiation]. Actas Dermosifiliogr; 2008 Jul-Aug;99(6):456-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Estudio inmunohistoquímico de la calretinina en el folículo piloso normal y neoplasias con diferenciación folicular.
  • RESULTS: Fifteen biopsies corresponded to trichilemmomas/inverted follicular keratosis and had staining for calretinin in the epithelium of the most superficial areas of the lesions and in squamous eddies.
  • Three were basal cell carcinomas with variable staining according to the type of follicular differentiation in each variant.
  • [MeSH-major] Hair Follicle / chemistry. Neoplasm Proteins / analysis. S100 Calcium Binding Protein G / analysis. Skin Neoplasms / chemistry
  • [MeSH-minor] Acanthoma / chemistry. Acanthoma / pathology. Calbindin 2. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / pathology. Carcinoma, Skin Appendage / chemistry. Carcinoma, Skin Appendage / pathology. Cell Differentiation. Epidermal Cyst / metabolism. Epidermal Cyst / pathology. Hamartoma / metabolism. Hamartoma / pathology. Humans. Neoplasms, Basal Cell / chemistry. Neoplasms, Basal Cell / pathology. Skin Diseases / metabolism. Skin Diseases / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18558053.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / Neoplasm Proteins; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


27. Tierney EP, Hanke CW: Cost effectiveness of Mohs micrographic surgery: review of the literature. J Drugs Dermatol; 2009 Oct;8(10):914-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A number of treatment modalities are currently in existence for non-melanoma skin cancer, including microscopically controlled surgical excision (e.g., Mohs micrographic surgery [MMS]), traditional surgical excision, radiation therapy, electrodessication and curettage, cryosurgery, photodynamic therapy and topical chemotherapeutic agents.
  • Previous studies have also indicated, across specialties, that dermatologists have the highest rates for complete removal of non melanoma skin cancer (NMSC) which are significantly greater than those for otolaryngologists (P>0.02) and plastic surgeons (P<0.0008).
  • This analysis confirms that MMS is a cost effective treatment, which is lower in cost than surgical excision, which often includes an ASC facility fee and a subsequent re-excision procedure.
  • [MeSH-major] Carcinoma, Basal Cell / economics. Mohs Surgery / economics. Skin Neoplasms / surgery
  • [MeSH-minor] Ambulatory Surgical Procedures / economics. Carcinoma, Squamous Cell / economics. Carcinoma, Squamous Cell / surgery. Cost-Benefit Analysis. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19852120.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


28. Meslemani DM, Jones L: An unusual presentation of nasal type NK/T-cell lymphoma of the nose. Laryngoscope; 2010;120 Suppl 4:S167
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of nasal type NK/T-cell lymphoma of the nose.
  • OBJECTIVES: Case report of a male with a rare nasal type NK/T cell lymphoma that presented as an aggressive nasal infection superimposed with squamous and basal cell carcinoma.
  • A review of the diagnosis, management, and prognosis nasal type NK/T cell lymphoma will be presented.
  • METHODS: Review of the literature for cases of nasal type NK/T cell lymphoma, with particular attention to its presentations.
  • RESULTS: Differential diagnosis includes aggressive infection of the nasal skin, carcinoma, and lymphoma.
  • CONCLUSION: No cases in the literature of NK/T cell lymphoma have been reported that presented with an aggressive infection with initial biopsies that revealed squamous cell and basal cell carcinoma, which led to surgical management and a definitive diagnosis of Nasal type NK/T cell lymphoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Rhinitis / pathology. Sinusitis / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21225765.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


29. Levine N: Chronic rash on the neck. Geriatrics; 2008 Mar;63(3):39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Exanthema / diagnosis
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Chronic Disease. Dermatitis, Contact / diagnosis. Diagnosis, Differential. Humans. Male. Prurigo / diagnosis. Pruritus / etiology. Scabies / diagnosis

  • MedlinePlus Health Information. consumer health - Rashes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312027.001).
  • [ISSN] 1936-5764
  • [Journal-full-title] Geriatrics
  • [ISO-abbreviation] Geriatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Guo ZL, Gao Y: [Expression of integrin-linked kinase in oral leukoplakia and early invasive carcinoma]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Mar;45(3):163-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of integrin-linked kinase in oral leukoplakia and early invasive carcinoma].
  • OBJECTIVE: To investigate the transmutation and significance of integrin-linked kinase (ILK) in oral leukoplakia and early invasive squamous cell carcinoma.
  • METHODS: Immunohistochemistry accompanied with periodic acid Schiff reaction (PAS) histochemistry was applied to detect the expression of ILK in 19 normal oral mucosa, 43 simple hyperplasia, 84 epithelial dysplasia, 54 early invasive carcinoma.
  • RESULTS: Among the oral leukoplakia and early invasive squamous cell carcinoma, dramatic positive expression of ILK was found in 163/181 (90%), but was negative in normal mucosa.
  • Along with the oral carcinogenesis, there was an obvious tendency of change-overed ILK staining from superfacial to the basal orientation, the stratum basale diverted into positive, and compared with scattering in cytoplasm, the location of ILK was prone to cytomembrane in epithelium.
  • In severe dysplasia and carcinoma in situ, there was a positive correlation between the basal layer and stroma expression of ILK (P = 0.029).
  • It was not only a weaker tincture of ILK in cancer nest than lesional epithelia, but also an augmentation of stroma staining in early invasive squamous cell carcinoma [76% (41/54)] by contrast with severe dysplasia [45% (18/40)].
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Leukoplakia, Oral / metabolism. Mouth Neoplasms / metabolism. Precancerous Conditions / metabolism. Protein-Serine-Threonine Kinases / metabolism

  • Genetic Alliance. consumer health - Leukoplakia.
  • Genetic Alliance. consumer health - Oral leukoplakia.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450685.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.1.- / integrin-linked kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


31. Ng J, Coroneo MT, Wakefield D, Di Girolamo N: Ultraviolet radiation and the role of matrix metalloproteinases in the pathogenesis of ocular surface squamous neoplasia. Invest Ophthalmol Vis Sci; 2008 Dec;49(12):5295-306
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet radiation and the role of matrix metalloproteinases in the pathogenesis of ocular surface squamous neoplasia.
  • PURPOSE: Ocular surface squamous neoplasia (OSSN) is an uncommon tumor of the corneal and conjunctival epithelium associated with risk of permanent visual impairment.
  • Cell viability as well as basal and UVB-modulated levels of MMPs and TIMPs from DCECs and NCECs was determined by immunoassays, zymography, and RT-PCR.
  • UVB radiation induced cell death and apoptosis at doses >/= 50 mJ/cm(2).
  • [MeSH-major] Carcinoma in Situ / enzymology. Conjunctiva / radiation effects. Conjunctival Neoplasms / enzymology. Epithelial Cells / radiation effects. Matrix Metalloproteinases / metabolism. Ultraviolet Rays
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Annexin A5 / metabolism. Apoptosis / radiation effects. Cell Survival. Female. Flow Cytometry. Gene Expression Regulation, Enzymologic / physiology. Humans. Immunoenzyme Techniques. Male. Middle Aged. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Inhibitor of Metalloproteinases / genetics. Tissue Inhibitor of Metalloproteinases / metabolism. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641285.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


32. Eide MJ, Krajenta R, Johnson D, Long JJ, Jacobsen G, Asgari MM, Lim HW, Johnson CC: Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data. Am J Epidemiol; 2010 Jan 1;171(1):123-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data.
  • Cancer registries usually exclude nonmelanoma skin cancers (NMSC), despite the large population affected.
  • A subset of charts was reviewed to verify NMSC diagnosis, including all records from HMO-enrollee members in 2007.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Serv Res. 2004 Dec;39(6 Pt 1):1733-49 [15533184.001]
  • [Cites] Med Care. 1999 May;37(5):436-44 [10335746.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):490-500 [16908356.001]
  • [Cites] Dermatol Surg. 2006 Dec;32(12):1473-9 [17199655.001]
  • [Cites] Health Serv Res. 2007 Oct;42(5):2056-69 [17850533.001]
  • [Cites] J Clin Epidemiol. 2008 Apr;61(4):373-9 [18313562.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1524-30 [11115165.001]
  • [Cites] J Natl Cancer Inst Monogr. 2005;(35):12-25 [16287881.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):425-9 [12637924.001]
  • [Cites] Health Serv Res. 2003 Jun;38(3):947-60 [12822920.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1105-8 [14578151.001]
  • [Cites] Am J Manag Care. 2004 Apr;10(4):257-62 [15124502.001]
  • [Cites] J Natl Cancer Inst. 1982 Aug;69(2):365-70 [6955543.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2489-95 [8640697.001]
  • [Cites] Qual Life Res. 1996 Apr;5(2):191-4 [8998487.001]
  • [Cites] J Am Acad Dermatol. 1998 Nov;39(5 Pt 1):698-703 [9810885.001]
  • [Cites] J Clin Epidemiol. 1999 Jan;52(1):57-64 [9973074.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [CommentIn] Am J Epidemiol. 2010 Jul 1;172(1):123-4; author reply 124 [20543030.001]
  • (PMID = 19969529.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / K23 AR051037; United States / NIAMS NIH HHS / AR / K23 AR051037-05; United States / NCI NIH HHS / CA / U19 CA079689; United States / NIAMS NIH HHS / AR / K23 AR 051037
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2796985
  •  go-up   go-down


33. Chen WL, Wang YJ, Bai ZB, Huang ZQ: [Mental neurovascular V-Y island advancement flap in functional reconstruction of partial lower lip defect]. Zhonghua Zheng Xing Wai Ke Za Zhi; 2008 Jan;24(1):34-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 7 patients with lower lip cancer (3 cases of basal cell carcinoma, 2 cases squamous cell carcinoma and 2 cases papillary carcinoma) underwent excision.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Lip Neoplasms / surgery. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437981.001).
  • [ISSN] 1009-4598
  • [Journal-full-title] Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery
  • [ISO-abbreviation] Zhonghua Zheng Xing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


34. Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB: Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst; 2010 Dec 15;102(24):1835-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
  • BACKGROUND: Preclinical studies indicate that the enzyme cyclooxygenase 2 plays an important role in ultraviolet-induced skin cancers.
  • We evaluated the efficacy and safety of celecoxib, a cyclooxygenase 2 inhibitor, as a chemopreventive agent for actinic keratoses, the premalignant precursor of nonmelanoma skin cancers, and for nonmelanoma skin cancers, including cutaneous squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs).
  • In exploratory analyses, we evaluated the number of nonmelanoma skin cancers combined and SCCs and BCCs separately per patient at 11 months after randomization using Poisson regression, after adjustment for patient characteristics and time on study.
  • However, at 11 months after randomization, there were fewer nonmelanoma skin cancers in the celecoxib arm than in the placebo arm (mean cumulative tumor number per patient 0.14 vs 0.35; rate ratio [RR] = .43, 95% confidence interval [CI] = 0.24 to 0.75; P = .003).
  • After adjusting for age, sex, Fitzpatrick skin type, history of actinic keratosis at randomization, nonmelanoma skin cancer history, and patient time on study, the number of nonmelanoma skin cancers was lower in the celecoxib arm than in the placebo arm (RR = 0.41, 95% CI = 0.23 to 0.72, P = .002) as were the numbers of BCCs (RR = 0.40, 95% CI = 0.18 to 0.93, P = .032) and SCCs (RR = 0.42, 95% CI = 0.19 to 0.93, P = .032).
  • CONCLUSIONS: Celecoxib may be effective for prevention of SCCs and BCCs in individuals who have extensive actinic damage and are at high risk for development of nonmelanoma skin cancers.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CELECOXIB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] J Invest Dermatol. 1994 Jun;102(6):4S-5S [8006434.001]
  • [Cites] J Invest Dermatol. 2000 Aug;115(2):273-7 [10951246.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):7-11 [11241303.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):926-9 [11289350.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5 Suppl 4):37-51 [12102579.001]
  • [Cites] Photochem Photobiol. 2002 Jul;76(1):73-80 [12126310.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1105-8 [14578151.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):920-7 [15184247.001]
  • [Cites] J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7 [15303784.001]
  • [Cites] Br J Dermatol. 1994 Oct;131(4):455-64 [7947197.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):170-5 [7857113.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):165-9 [7622291.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1302-7 [8883422.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):957-61 [9367070.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):723-9 [9635856.001]
  • [Cites] Br J Dermatol. 1998 Dec;139(6):1033-9 [9990367.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1939-44 [10506108.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Br J Dermatol. 2005 Mar;152(3):518-23 [15787821.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):931-9 [16186186.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):966-72 [16310056.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):490-500 [16908356.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2546-8 [17132769.001]
  • [Cites] N Engl J Med. 2007 Jul 26;357(4):360-9 [17652651.001]
  • [Cites] Mol Carcinog. 2007 Aug;46(8):692-8 [17443745.001]
  • [Cites] Mol Carcinog. 2007 Dec;46(12):981-92 [17583568.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):463-76 [18248498.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32 [18410798.001]
  • [Cites] Circulation. 2008 Apr 22;117(16):2104-13 [18378608.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jun;66(3):208-17 [18304833.001]
  • [Cites] Mol Cancer Res. 2008 Jun;6(6):1003-16 [18567804.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):21-31 [19138933.001]
  • [Cites] J Invest Dermatol. 2009 Apr;129(4):1016-25 [18843292.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):276-83 [19226541.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):35-47 [20051371.001]
  • [Cites] Arch Dermatol. 2010 Mar;146(3):283-7 [20231499.001]
  • [Cites] Arch Dermatol. 2010 Apr;146(4):388-95 [20157019.001]
  • [Cites] Australas J Dermatol. 1983 Aug;24(2):79-82 [6661117.001]
  • [Cites] N Engl J Med. 1988 Jun 23;318(25):1633-7 [3287161.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):328-32 [1738183.001]
  • [Cites] JAMA. 1992 Jun 24;267(24):3305-10 [1597912.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1272-5 [8145782.001]
  • [CommentIn] J Natl Cancer Inst. 2010 Dec 15;102(24):1815-7 [21115881.001]
  • [CommentIn] Arch Dermatol. 2012 May;148(5):638-40 [22782153.001]
  • (PMID = 21115882.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-85183; United States / NIAMS NIH HHS / AR / P30 AR050948; United States / NCI NIH HHS / CA / P30 CA013148
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  • [Other-IDs] NLM/ PMC3001966
  •  go-up   go-down


35. Wei CC, Sanfilippo NJ, Myssiorek D: Re-irradiation of metastatic disease in the neck from xeroderma pigmentosum. Curr Oncol; 2010 Jun;17(3):83-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re-irradiation of metastatic disease in the neck from xeroderma pigmentosum.
  • BACKGROUND: Xeroderma pigmentosum, an autosomal recessive disease that occurs with a frequency of 1:250,000, is caused by a genetic defect in nucleotide excision repair enzymes.
  • Mutation of these enzymes leads to the development of multiple basal cell and squamous cell carcinomas.
  • OBJECTIVES: We present a case of xeroderma pigmentosum in a patient with cervical and intraparotid metastatic disease from recurrent cutaneous squamous cell carcinomas of the face and scalp, treated with neck dissection and re-irradiation.
  • With the illustrative case report, we include a literature review of diagnosis, prognostic factors, and treatment, with emphasis on surgical and radiation treatment of cervical metastatic disease from recurrent skin carcinomas.
  • CASE PRESENTATION: A xeroderma pigmentosum patient presented to our clinic with a 2-cm right submental and 1-cm right infra-auricular mass after resection of multiple squamous cell carcinomas of the scalp and face, and external-beam radiation therapy to the right face and neck.
  • Fine-needle aspiration biopsy of the submental mass revealed poorly differentiated squamous cell carcinoma.
  • Surgical pathology revealed 3 level ia and supraclavicular lymph nodes that were positive for metastatic squamous cell carcinoma.
  • Re-irradiation to the entire right hemi-neck and left submandibular nodal region was performed using opposed oblique portals for the upper neck and a low anterior en face hemi-neck portal.
  • CONCLUSIONS: To our knowledge, this is the first case report in the literature of a patient with xeroderma pigmentosum who subsequently developed metastatic disease from recurrent cutaneous squamous cell carcinoma.
  • Because of the rarity of xeroderma pigmentosum, this case report is also the first to describe re-irradiation to treat cervical and intraparotid metastatic disease in a xeroderma pigmentosum patient.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cutan Med Surg. 1998 Jan;2(3):153-8 [9479081.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):143-54 [11054518.001]
  • [Cites] Anticancer Drugs. 2006 Feb;17(2):133-8 [16428930.001]
  • [Cites] Adv Exp Med Biol. 2008;637:19-27 [19181107.001]
  • [Cites] Radiother Oncol. 2006 Oct;81(1):1-8 [16971009.001]
  • [Cites] Eur J Dermatol. 2009 Mar-Apr;19(2):163-5 [19106040.001]
  • [Cites] Br J Radiol. 2006 Jun;79(942):510-7 [16714754.001]
  • (PMID = 20567629.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2880910
  • [Keywords] NOTNLM ; Xeroderma pigmentosum / head-and-neck cancer / radiation / re-irradiation
  •  go-up   go-down


36. Kim TH, Chiera SL, Linder KE, Trempus CS, Smart RC, Horowitz JM: Overexpression of transcription factor sp2 inhibits epidermal differentiation and increases susceptibility to wound- and carcinogen-induced tumorigenesis. Cancer Res; 2010 Nov 1;70(21):8507-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sp proteins are evolutionarily conserved transcription factors required for the expression of a wide variety of genes that are critical for development and cell cycle progression.
  • Deregulated expression of certain Sp proteins is associated with the formation of a variety of human tumors; however, direct evidence that any given Sp protein is oncogenic has been lacking.
  • Here, we report that Sp2 protein abundance in mice increases in concert with the progression of carcinogen-induced murine squamous cell carcinomas.
  • Transgenic mice specifically overexpressing murine Sp2 in epidermal basal keratinocytes were highly susceptible to wound- and carcinogen-induced papillomagenesis.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Gene. 1999 Oct 1;238(2):291-300 [10570957.001]
  • [Cites] Biochim Biophys Acta. 2010 Jul;1799(7):520-31 [20353838.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32387-90 [10964907.001]
  • [Cites] J Invest Dermatol. 2000 Nov;115(5):788-94 [11069615.001]
  • [Cites] Carcinogenesis. 2001 Apr;22(4):651-9 [11285202.001]
  • [Cites] J Cell Physiol. 2001 Aug;188(2):143-60 [11424081.001]
  • [Cites] Mol Biol Cell. 2002 Jan;13(1):382-91 [11809846.001]
  • [Cites] Mol Cell Endocrinol. 2002 Sep 30;195(1-2):27-38 [12354670.001]
  • [Cites] J Invest Dermatol. 2003 Apr;120(4):501-11 [12648211.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):963-8 [14708593.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13911-24 [14726517.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3072-8 [15126343.001]
  • [Cites] J Pathol. 2004 Nov;204(4):355-66 [15495218.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Cell. 1983 Feb;32(2):599-606 [6297803.001]
  • [Cites] Nucleic Acids Res. 1990 Jun 11;18(11):3203-9 [2192357.001]
  • [Cites] Science. 1990 Jun 29;248(4963):1656-60 [2163544.001]
  • [Cites] Nature. 1990 Aug 23;346(6286):756-60 [2167455.001]
  • [Cites] Genes Dev. 1991 May;5(5):714-27 [1709129.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4334-41 [7519120.001]
  • [Cites] Differentiation. 1994 Nov;58(1):53-64 [7532601.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7634-8 [8755527.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):445-71 [9034603.001]
  • [Cites] Mol Carcinog. 1997 Sep;20(1):108-14 [9328441.001]
  • [Cites] Chem Biol. 1995 Feb;2(2):83-9 [9383408.001]
  • [Cites] J Invest Dermatol. 1998 Jun;110(6):939-45 [9620302.001]
  • [Cites] Nucleic Acids Res. 1999 Aug 1;27(15):2991-3000 [10454592.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1837-44 [10469632.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):7181-90 [10490653.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):861-7 [15705884.001]
  • [Cites] Genomics. 2005 May;85(5):551-6 [15820306.001]
  • [Cites] Dev Growth Differ. 2005 May;47(4):201-11 [15921495.001]
  • [Cites] Eur J Cell Biol. 2005 Aug;84(8):709-18 [16180309.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2438-48 [16209919.001]
  • [Cites] Nat Med. 2005 Dec;11(12):1351-4 [16288281.001]
  • [Cites] Biochem J. 2006 Jan 1;393(Pt 1):397-409 [16201967.001]
  • [Cites] Cell Cycle. 2006 Jan;5(2):184-90 [16340309.001]
  • [Cites] Mol Biol Cell. 2006 Apr;17(4):1711-22 [16467376.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4173-81 [17483328.001]
  • [Cites] Transgenic Res. 2008 Aug;17(4):749-54 [18085422.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7278-82 [18794114.001]
  • [Cites] J Clin Invest. 2009 Jul;119(7):1794-805 [19587454.001]
  • [Cites] J Biol Chem. 2010 Feb 5;285(6):4153-64 [19959469.001]
  • [Cites] PLoS One. 2010;5(3):e9587 [20221402.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1561-70 [10749124.001]
  • (PMID = 20959487.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM065405; United States / NCI NIH HHS / CA / R01 CA105313; United States / NIGMS NIH HHS / GM / R01 GM065405; United States / NCI NIH HHS / CA / R01 CA046637; United States / NCI NIH HHS / CA / CA105313
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Keratin-5; 0 / RNA, Messenger; 148710-93-4 / Sp2 Transcription Factor; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ NIHMS237683; NLM/ PMC2970695
  •  go-up   go-down


37. Moergel M, Abt E, Stockinger M, Kunkel M: Overexpression of p63 is associated with radiation resistance and prognosis in oral squamous cell carcinoma. Oral Oncol; 2010 Sep;46(9):667-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of p63 is associated with radiation resistance and prognosis in oral squamous cell carcinoma.
  • BACKGROUND: The tumor suppressor homologue p63 is expressed in basal and parabasal layers of intraoral mucosa.
  • Full length transcripts with transactivational domain (TA forms) present with homology to p53 and implicate functions governing cell proliferation, differentiation and apoptosis control.
  • Quantification of the labeling index (Li) based on the relation of p63 positive cells to overall tumor cell count.
  • Tumors with a p63 positive cell count>63.1% showed increased resistance to radiation (p=0.027).
  • CONCLUSIONS: The results of this analysis advocate p63 expression in pre-treatment tumor tissue to be a marker of radiation resistance in OSCC, with high expression levels being associated with poor radiation response and shorter survival.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Mouth Neoplasms / metabolism. Radiation Tolerance. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20656547.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


38. Kudrina MI, Vinogradova NN, Kolen'ko NG, Zaev SN: [Skin tumours and primary multiple malignant neoplasms]. Klin Med (Mosk); 2009;87(2):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin tumours and primary multiple malignant neoplasms].
  • The structure of recurrent malignant neoplasms was analysed in a group of patients followed up on a permanent basis after the treatment for skin cancer.
  • Observation of 2801 patients with primary basal and squamous cell skin cancer during 32 years (1975-2006) revealed 740 recurrent malignant neoplasms largely affecting skin, gastrointestinal tract, lungs, mammary and prostate glands.
  • [MeSH-major] Breast Neoplasms / epidemiology. Gastrointestinal Neoplasms / epidemiology. Neoplasms, Multiple Primary / epidemiology. Prostatic Neoplasms / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Incidence. Male. Mass Screening / methods. Retrospective Studies. Russia / epidemiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348305.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


39. Hansen C, Wilkinson D, Hansen M, Soyer HP: Factors contributing to incomplete excision of nonmelanoma skin cancer by Australian general practitioners. Arch Dermatol; 2009 Nov;145(11):1253-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors contributing to incomplete excision of nonmelanoma skin cancer by Australian general practitioners.
  • OBJECTIVE: To study rates of incomplete excision of basal (BCC) and squamous (SCC) cell cancer by Australian general practitioners with a special interest.
  • SETTING: A network of 15 primary care skin cancer clinics across Australia.
  • PARTICIPANTS: Fifty-seven physicians performing excisions of 9417 BCCs and SCCs in a single network of 15 primary care skin cancer clinics across Australia between 2005 and 2007.
  • Incomplete BCC and SCC excisions were more frequent on the head and neck (282 of 2872 excisions [9.8%] and 97 of 861 [11.3%], respectively) than elsewhere.
  • Of all BCC excisions, 67.3% were once-off excisions with no previous biopsy, and these excisions were more likely to be incomplete (odds ratio, 1.73; 95% confidence interval, 1.36-2.20) than those with a previous biopsy.
  • There was, however, substantial variation in frequency of incomplete excision between clinics for BCC (ranging from 3.3% to 24.7%) and SCC (ranging from 0% to 17.2%) and between physicians within clinics (BCC ranging from 0% to 31.1%, and SCC ranging from 0% to 23.5%).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Clinical Competence. Dermatology / methods. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917954.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Nguyen TH: Mohs bashing out of hand. Plast Reconstr Surg; 2005 Jan;115(1):361-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Ambulatory Surgical Procedures / adverse effects. Ambulatory Surgical Procedures / education. Ambulatory Surgical Procedures / psychology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Dermatology / education. Head and Neck Neoplasms / surgery. Humans. Outpatients / psychology. Patient Satisfaction. Postoperative Complications / etiology. Postoperative Complications / prevention & control. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Plast Reconstr Surg. 2004 Feb;113(2):774-5 [14758268.001]
  • (PMID = 15622305.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


41. Sobel G, Szabó I, Páska C, Kiss A, Kovalszky I, Kádár A, Paulin F, Schaff Z: Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia. Pathol Oncol Res; 2005;11(1):26-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia.
  • Cell-cell and cell-extracellular matrix interaction is crucial in tumor progression.
  • Paraffin sections of 50 samples were studied by immunohistochemistry, including cervical intraepithelial neoplasias (CINI-II-III), in situ carcinomas (CIS) and normal cervical samples.
  • Occludin and CLDN-2 were found colocalized in the basal layer, while syndecan-1 and CLDN-1, -4 and -7 were coexpressed in the parabasal and intermedier layers in normal epithelia.
  • The obtained data suggest that significant changes occur in the composition of cell adhesion complexes even in early stages of cervical carcinogenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion. Cervical Intraepithelial Neoplasia / metabolism. Extracellular Matrix / metabolism
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervix Uteri / metabolism. Cervix Uteri / pathology. Claudin-1. Claudin-4. Claudins. Epithelial Cells / metabolism. Female. Humans. Immunoenzyme Techniques. Membrane Glycoproteins / metabolism. Membrane Proteins / metabolism. Neoplasm Staging. Occludin. Proteoglycans / metabolism. Syndecan-1. Syndecans. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1999 Dec;75(3):372-8 [10600292.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Jan 2;57(1):111-21 [15518924.001]
  • [Cites] Semin Cancer Biol. 2002 Jun;12(3):173-86 [12083848.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] Eur J Cell Biol. 2002 Aug;81(8):419-35 [12234014.001]
  • [Cites] Hum Pathol. 2005 Feb;36(2):162-9 [15754293.001]
  • [Cites] Diagn Mol Pathol. 2004 Dec;13(4):234-40 [15538114.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Jun;286(6):C1213-28 [15151915.001]
  • [Cites] Am J Dermatopathol. 2000 Apr;22(2):119-22 [10770430.001]
  • [Cites] J Membr Biol. 2003 Aug 1;194(3):187-97 [14502431.001]
  • [Cites] Jpn J Cancer Res. 2001 Oct;92(10):1062-73 [11676857.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1539-50 [9647647.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Apr;2(4):285-93 [11283726.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):1-6 [11241302.001]
  • [Cites] J Pathol. 1994 Jun;173(2):97-104 [8089811.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Int J Cancer. 1999 Feb 9;80(4):527-32 [9935152.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):141-9 [14704716.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):328-34 [15327539.001]
  • [Cites] Int J Oncol. 2002 Jan;20(1):39-43 [11743640.001]
  • [Cites] J Virol. 2001 Feb;75(3):1565-70 [11152531.001]
  • [Cites] Am J Pathol. 1996 Mar;148(3):865-75 [8774141.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Aug;287(2):F305-18 [15068973.001]
  • [Cites] Lung Cancer. 2001 Jun;32(3):297-305 [11390011.001]
  • [Cites] Exp Cell Res. 2003 Jun 10;286(2):288-97 [12749857.001]
  • [Cites] Cell. 1996 Feb 9;84(3):345-57 [8608588.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):589-600 [8106556.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):558-64 [10027330.001]
  • [Cites] J Virol. 2003 Dec;77(24):13125-35 [14645569.001]
  • [Cites] J Cell Sci. 2004 May 15;117(Pt 12):2435-47 [15159449.001]
  • [Cites] J Anat. 2004 Oct;205(4):257-66 [15447685.001]
  • [Cites] J Pathol. 1994 Apr;172(4):349-55 [8207616.001]
  • [Cites] Blood. 2002 Jul 15;100(2):610-7 [12091355.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):575-81 [12841864.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3709-15 [1692766.001]
  • [Cites] Oncol Res. 2001;12(11-12):469-76 [11939410.001]
  • [Cites] Virchows Arch. 2004 Nov;445(5):472-6 [15232740.001]
  • [Cites] Jpn J Cancer Res. 2001 Oct;92(10):1074-81 [11676858.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):159-64 [14991532.001]
  • (PMID = 15800679.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN2 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / OCLN protein, human; 0 / Occludin; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans
  •  go-up   go-down


42. Cantwell MM, Murray LJ, Catney D, Donnelly D, Autier P, Boniol M, Fox C, Middleton RJ, Dolan OM, Gavin AT: Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br J Cancer; 2009 Jan 13;100(1):174-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland.
  • Among all 14,500 incident cases of basal cell carcinoma (BCC), 6405 squamous cell carcinomas (SCC) and 1839 melanomas reported to the Northern Ireland Cancer Registry between 1993 and 2002, compared with the general population, risk of new primaries after BCC or SCC was increased by 9 and 57%, respectively.
  • [MeSH-major] Neoplasms, Second Primary / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Colorectal Neoplasms / epidemiology. Female. Humans. Incidence. Ireland / epidemiology. Male. Melanoma / epidemiology. Middle Aged. Sunlight. Vitamin D / administration & dosage

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):678-83 [11333289.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 19;87(14):1061-6 [7616597.001]
  • [Cites] Ann Intern Med. 1996 Nov 15;125(10):852-4 [8928994.001]
  • [Cites] Int J Cancer. 1999 Feb 9;80(4):511-5 [9935149.001]
  • [Cites] Am J Prev Med. 2007 Mar;32(3):210-6 [17296473.001]
  • [Cites] Am J Epidemiol. 2008 Jun 15;167(12):1421-9 [18424428.001]
  • [Cites] Am J Epidemiol. 2007 Apr 15;165(8):966-72 [17255116.001]
  • [Cites] Br J Dermatol. 2007 Jun;156(6):1301-7 [17535230.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(11):1701-12 [17540555.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):12-5 [17967529.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):668-74 [17208438.001]
  • (PMID = 19127269.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ PMC2634689
  •  go-up   go-down


43. Shome D, Bell D, Esmaeli B: Eyelid carcinoma in patients with systemic lymphoma. J Ophthalmic Vis Res; 2010 Jan;5(1):38-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid carcinoma in patients with systemic lymphoma.
  • PURPOSE: To describe a series of patients with Non-Hodgkin's lymphoma (NHL) and concomitant eyelid carcinoma.
  • METHODS: In this non-comparative interventional case series, we retrospectively reviewed the medical records of 5 patients with NHL who developed eyelid carcinoma.
  • Systemic lymphoma had been diagnosed 1 to 72 months prior to development of the eyelid carcinoma.
  • The lesions were basal cell carcinoma in three, and squamous cell carcinoma in two cases.
  • Four patients underwent surgical excision of the carcinoma and one patient was awaiting surgical treatment after completing systemic chemotherapy.
  • Three subjects had high-grade carcinomas.
  • CONCLUSIONS: Systemic lymphoma may be associated with aggressive eyelid carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2008 Nov-Dec;24(6):444-9 [19033839.001]
  • [Cites] Am J Ophthalmol. 1986 Apr 15;101(4):480-2 [3515953.001]
  • [Cites] Arch Ophthalmol. 1980 Oct;98(10):1771-2 [7000053.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1847-50 [8956805.001]
  • [Cites] Acta Haematol. 1997;98(1):44-6 [9210914.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):641-5 [10048959.001]
  • [Cites] Dermatology. 2001;202(4):359-61 [11455161.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Curr Treat Options Oncol. 2004 Jun;5(3):215-23 [15115650.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):507-13 [15160912.001]
  • [Cites] Histopathology. 2004 Aug;45(2):162-70 [15279635.001]
  • [Cites] Arch Dermatol. 2004 Aug;140(8):985-8 [15313816.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):49-54 [15621780.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):38-42; discussion 42 [15720094.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1051-5 [16019557.001]
  • [Cites] Skinmed. 2005 Sep-Oct;4(5):300-4 [16282752.001]
  • [Cites] Australas J Dermatol. 2006 Nov;47(4):231-6 [17034463.001]
  • (PMID = 22737325.001).
  • [ISSN] 2008-2010
  • [Journal-full-title] Journal of ophthalmic & vision research
  • [ISO-abbreviation] J Ophthalmic Vis Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3380669
  • [Keywords] NOTNLM ; Eyelid Cancer / Immunosuppression / Squamous Cell Carcinoma / Systemic Lymphoma
  •  go-up   go-down


44. Hirai E, Yamamoto K, Yamamoto N, Yamashita Y, Kounoe T, Kondo Y, Yonemasu H, Takahashi T, Kurokawa H: Basaloid squamous cell carcinoma of the mandible: report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Nov;108(5):e54-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the mandible: report of two cases.
  • Basaloid squamous cell carcinoma is a rare aggressive malignancy that is a distinct variant of squamous cell carcinoma.
  • This report presents 2 cases of basaloid squamous cell carcinoma in the gingiva.
  • Both tumors were diagnosed histopathologically as basaloid squamous cell carcinoma.
  • In case 1, the patient underwent wide resection of the gingival tumor with a partial mandibulectomy and ipsilateral functional neck dissection.
  • In case 2, the patient underwent wide resection of the gingival tumor after local irradiation (60 Gy).
  • At the time of writing, both patients remained in good health and free of disease.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Gingival Neoplasms / pathology. Mandibular Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836714.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Lee WY, Huang SC, Hsu KF, Tzeng CC, Shen WL: Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. Gynecol Oncol; 2008 Feb;108(2):377-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Malignant phenotypic traits are caused by microenvironmental selection pressures during carcinogenesis.
  • Hypoxia can drive a tumor toward a more aggressive malignant phenotype.
  • METHODS: We analyzed the expression of the hypoxia-regulated genes, including hypoxia-inducible factor-1alpha (HIF-1alpha), erythropoietin (Epo), vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX), and MET, in cervical cell lines and human tissue samples of cervical intraepithelial neoplasia (CIN I-III) and invasive squamous cell carcinoma (ISCC).
  • RESULTS: CAIX and MET were expressed in cervical carcinoma cell lines, but not in normal or human papillomavirus-immortalized cervical cells.
  • In clinical tissue samples, Epo, VEGF, GLUT1, and CAIX were not detected in normal squamous epithelia.
  • HIF-1alpha and MET expression was confined to the basal cells in normal squamous epithelia and was detected in the dysplastic cells of CIN and ISCC.
  • CONCLUSIONS: The role of HIF-1alpha and MET changes from response to proliferation to tumor progression during cervical carcinogenesis.
  • GLUT1 expression, a glycolytic phenotype adaptive to glycolysis, occurs early during cervical carcinogenesis and is a specific marker for dysplasia or carcinoma.
  • MET and CAIX may contribute tumor progression in later stage.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Cell Transformation, Neoplastic / genetics. Cervical Intraepithelial Neoplasia / genetics. Gene Expression Regulation, Neoplastic. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Blotting, Western. Cell Hypoxia / genetics. Cell Line, Tumor. Erythropoietin / biosynthesis. Erythropoietin / genetics. Female. Glucose Transporter Type 1 / biosynthesis. Glucose Transporter Type 1 / genetics. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Hypoxia-Inducible Factor 1, alpha Subunit / genetics. Immunohistochemistry. Middle Aged. Papillomaviridae / physiology


46. Panizzon RG: [Dermatologic radiotherapy]. Hautarzt; 2007 Aug;58(8):701-10, quiz 711
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Another important parameter is the half-value depth which should correspond to the depth of the tumor below the skin surface.
  • In this way the skin is not over-exposed to radiation treatment.
  • Indications for radiotherapy of malignant skin tumors include basal cell carcinoma, squamous cell carcinoma, severe actinic keratoses, lentigo maligna, lentigo maligna melanoma, Merkel cell carcinoma, and Kaposi sarcoma, as well as T- and B-cell lymphomas.
  • Most patients with malignant skin tumors require life-long monitoring after radiotherapy.
  • [MeSH-major] Precancerous Conditions / radiotherapy. Skin Diseases / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Eczema / radiotherapy. Humans. Keloid / radiotherapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell, Cutaneous / radiotherapy. Palliative Care. Psoriasis / radiotherapy. Radiotherapy Dosage. Sarcoma, Kaposi / radiotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639284.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF, Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group: Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer; 2009 Jun 1;115(11):2523-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial.
  • BACKGROUND: Actinic keratoses (AKs) are established as direct precursors of squamous cell carcinoma (SCC), but there is significant controversy regarding the rate at which AKs progress to SCC.
  • The authors of this report studied a high-risk population to estimate the risk of progression of AK to SCC and to basal cell carcinoma (BCC) and the risk of spontaneous regression of untreated AKs.
  • CONCLUSIONS: In the current study, the authors quantified the malignant potential of clinically diagnosed AKs for both SCC and BCC, although many did not persist, and the results suggested that AKs may play a greater role in the overall burden of keratinocyte carcinomas than previously documented.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Disease Progression. Keratosis, Actinic / pathology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382202.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01AR49342; United States / NCI NIH HHS / CA / R01CA106592; United States / NCI NIH HHS / CA / R01CA106807; United States / NCI NIH HHS / CA / R25CA087972
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Investigator] Weinstock MA; Marcolivio K; Weinstock M; Bingham S; DiGiovanna J; Hall R; Naylor M; Taylor JR; Vertrees J; White C; Hall R; Hannah D; Eilers D; Liang T; Sakla N; Kreuger A; Cole G; Jeffes E; Labrador T; Taylor JR; Kirsner R; Kerri JE; Falabela AG; Givens M; Naylor M; Benson MB; Perry L; Kalivas J; Yanni C; Targovnik S; Austin J; Collier S; Collins JF; Bingham S; Calvert B; Connor P; Crigler C; Davis D; Grubb P; Kelly J; Kirk G; Lawson K; Linzy L; Palmer L; Rhoads M; Sather M; Copeland E; Fye C; Gagne W; de Naranjo PG; Messick C; Vertrees J; Piepkorn M; White C; Lew R; Braverman I; Cole B; Kalish R; McLean D; Thiers B
  •  go-up   go-down


48. Fine JD, Mellerio JE: Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol; 2009 Sep;61(3):387-402; quiz 403-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some epidermolysis bullosa subtypes are at risk for severe injury of the bone marrow, musculoskeletal system, heart, kidney, and teeth, and for the development of squamous cell carcinoma, basal cell carcinoma, or malignant melanoma.
  • [MeSH-minor] Carcinoma, Squamous Cell / complications. Education, Medical, Continuing. Humans. Mouth Diseases / etiology. Skin Neoplasms / complications


49. Shimizu Y, Yoshida T, Kato M, Hirota J, Ono S, Nakagawa M, Kobayashi T, Kubota K, Asaka M: Low-grade dysplasia component in early invasive squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol; 2010 Feb;25(2):314-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade dysplasia component in early invasive squamous cell carcinoma of the esophagus.
  • BACKGROUND AND AIMS: It has not been determined whether low-grade squamous dysplasia (LGD) of the esophagus is a precancerous lesion or not.
  • If LGD progresses to squamous cell carcinoma, early carcinoma lesions that have such a natural history might contain a remaining LGD component.
  • METHODS: The lesions in the 68 patients with early invasive squamous cell carcinoma who underwent endoscopic mucosal resection were examined for the presence of an LGD component.
  • If LGD components were observed, the degrees of architectural and cytological abnormalities of LGD components and those of tumor invasive fronts in the same lesions were studied.
  • RESULTS: Histological examination of resected specimens confirmed LGD components in 43% of the squamous cell carcinoma lesions.
  • Mean score for the degrees of cytological abnormalities of LGD component was similar to that of tumor invasive front (P = 0.457) and significantly higher than that of small LGD lesions (P < 0.001).
  • CONCLUSION: Our results indicate the possibility that the lesion was formed by a combination of small lesions that arose as a multicentric occurrence of squamous cell carcinoma and dysplasia.
  • Our results also suggest that an LGD component would transform to carcinoma along with tumor progression.
  • However, the concept of 'basal cell layer type carcinoma in situ' may be suitable for squamous cell lesions with a high degree of cytological abnormalities confined to the lower half of the epithelium.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Esophagus / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Cell Transformation, Neoplastic / pathology. Disease Progression. Esophagoscopy. Female. Humans. Male. Middle Aged. Mucous Membrane / pathology. Neoplasm Invasiveness. Neoplasm Staging

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968747.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


50. Hernández-Martín A, Arias-Palomo D, Barahona E, Hidalgo C, Muñoz C, García-Higuera I: [Analysis of surgical treatment for nonmelanoma skin cancer performed by dermatologists in a public hospital: clinical-pathological correlation, use of hospital resources, and waiting list time from diagnosis]. Actas Dermosifiliogr; 2007 Dec;98(10):694-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of surgical treatment for nonmelanoma skin cancer performed by dermatologists in a public hospital: clinical-pathological correlation, use of hospital resources, and waiting list time from diagnosis].
  • [Transliterated title] Análisis del tratamiento quirúrgico del cáncer cutáneo no melanoma cuando es realizado por dermatólogos en un hospital público: correlación anatomoclínica, empleo de recursos hospitalarios y tiempo de espera desde el diagnóstico.
  • BACKGROUND: Nonmelanoma skin cancer is the most common form of cancer in humans.
  • No studies have been published addressing differences in the management of surgical treatment for nonmelanoma skin cancer according to the specialties involved.
  • OBJECTIVES: To assess the preoperative diagnostic accuracy and the use of health care resources when surgical treatment of nonmelanoma skin cancer is done by dermatologists belonging to the Spanish national health service.
  • METHODS: A prospective observational study was carried out over a period of 36 months using data corresponding to all patients diagnosed with nonmelanoma skin cancer and treated surgically in the Dermatology Department of Complejo Hospitalario de Burgos, Spain.
  • Data were analyzed for clinical-pathological correlation, complexity of the intervention, use of health care resources, and time elapsed between clinical diagnosis and surgery.
  • RESULTS: The study included 448 patients and 521 skin lesions suspected to be nonmelanoma skin cancer (basal cell carcinoma or squamous cell carcinoma).
  • Diagnosis was exclusively clinical in 487 tumors and a clinical-pathological correlation of 84.39% was observed.
  • In 349 patients (77.90%) the procedure was performed on an outpatient basis, 73 (16.29%) required a short stay in the surgical day care unit, and 26 (5.80%) required hospital admission.
  • The mean (SD) delay from clinical diagnosis to surgery was 68.44 (42.22) days, with a median delay of 60 days.
  • CONCLUSIONS: Dermatology specialists are highly qualified to diagnose malignant skin tumors and accurately identify those patients requiring surgery.
  • [MeSH-major] Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Actas Dermosifiliogr. 2008 Mar;99(2):170
  • (PMID = 18035027.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


51. Si Y, Wei H, Huang B, Lan G, Lu J, Zhang Z, Li B, Zhou R: [The histomorphological changes of the nasal mucosa in nasopharyngeal carcinoma patients postradiotherapy]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Jun;22(12):536-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The histomorphological changes of the nasal mucosa in nasopharyngeal carcinoma patients postradiotherapy].
  • OBJECTIVE: To study the histomorphology at the nasal mucosa in the nasopharyngeal carcinoma (NPC) patients postradiotherapy.
  • The changes of the mucosal histomorphology include cells and cilia in epithelium, basal layer, glandular and glandular cells in lamina propria.
  • The mucosal changes of epithelium and cilia desquamating, basal layer thickening, decrease of the serous glands and increase of the mucous glands in lamina propria were observed under light microscope.
  • CONCLUSION: We found that the various extent of destruction of the nasal mucosa may be the pathological basis of complicating nasal or sinusitis in NPC patients postradiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Nasal Mucosa / pathology. Nasopharyngeal Neoplasms / pathology

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18800678.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


52. Gasparian NA, Pozharisskiĭ KM, Zharinov GM, Vinokurov VL, Kuznetsova ME, Neklasova NIu: [Immunohistochemical study of the predictive value of oncoproteins p53, HER-2 and c-myc during radiotherapy for squamous cell carcinoma of the cervix]. Vopr Onkol; 2007;53(4):439-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical study of the predictive value of oncoproteins p53, HER-2 and c-myc during radiotherapy for squamous cell carcinoma of the cervix].
  • Out of 80 patients with squamous cell cervical carcinoma (stage II-III), p53 expression was observed in 30% of tumors prior to treatment and 49% in the course of radiotherapy.
  • Hence, p53 expression may be used as a predictive factor in radiotherapy for cervical carcinoma.
  • No correlation was found between p53 expression, on the one hand, and such basal clinico-morphological parameters as stage, morphological pattern and tumor cell differentiation, on the other.
  • HER2(3t) overexpression occurred in 2 (2.5%) which seems to point to its insignificant role in squamous cell cervical carcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / radiotherapy. Proto-Oncogene Proteins c-myc / metabolism. Receptor, ErbB-2 / metabolism. Tumor Suppressor Protein p53 / metabolism. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Survival Analysis. Up-Regulation / radiation effects


53. Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M: Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev; 2010 Nov;19(11):2942-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photosensitizing medication use and risk of skin cancer.
  • Whether use of these medications affects skin cancer risk, however, is unclear.
  • METHODS: Using a cohort of all Danish residents ≥15 years old in 1995 to 2006 (n = 4,761,749) and information from Danish national registers, we examined associations between use of photosensitizing medications and risk of basal cell carcinoma, cutaneous malignant melanoma, Merkel cell carcinoma, and squamous cell carcinoma.
  • RESULTS: Users of only 2 of 19 medications for long-term use (methyldopa and furosemide) had both a ≥20% increased risk of skin cancer (compared with nonusers) and an increase in risk with increasing duration of use; these effects were limited to basal cell carcinoma and squamous cell carcinoma, respectively.
  • In contrast, 8 of 10 medications for short-term use were associated with both a ≥20% increased risk of skin cancer and an increase in risk with increasing use for at least one of the four cancers.
  • CONCLUSION: We found little evidence of an increased risk of skin cancer among users of photosensitizing medications for long-term daily use, but could not rule out the possibility that users of some photosensitizing medications for short-term use may have an increased risk of skin cancer.
  • Our study examined the effect of a wide range of photosensitizing medications on skin cancer risk and suggests that future work should focus on photosensitizing medications for short-term use.
  • [MeSH-major] Photosensitivity Disorders / chemically induced. Prescription Drugs / adverse effects. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20861398.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prescription Drugs
  •  go-up   go-down


54. Hussein MR: Ultraviolet radiation and skin cancer: molecular mechanisms. J Cutan Pathol; 2005 Mar;32(3):191-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet radiation and skin cancer: molecular mechanisms.
  • UV radiation can damage DNA and thus mutagenize several genes involved in the development of the skin cancer.
  • During this process, variable alterations of the oncogenic, tumor-suppressive, and cell-cycle control signaling pathways occur.
  • These pathways include (a) mutated PTCH (in the mitogenic Sonic Hedgehog pathway) and mutated p53 tumor-suppressor gene in basal cell carcinomas, (b) an activated mitogenic ras pathway and mutated p53 in squamous cell carcinomas, and (c) an activated ras pathway, inactive p16, and p53 tumor suppressors in melanomas.
  • This review presents background information about the skin optics, UV radiation, and molecular events involved in photocarcinogenesis.
  • [MeSH-major] DNA / radiation effects. Neoplasms, Radiation-Induced / etiology. Skin Neoplasms / etiology. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / genetics. DNA Damage / genetics. Humans. Melanoma / etiology. Melanoma / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701081.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Number-of-references] 112
  •  go-up   go-down


55. Katoh M, Katoh M: Notch signaling in gastrointestinal tract (review). Int J Oncol; 2007 Jan;30(1):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Notch signaling is one of key pathways constituting the stem cell signaling network.
  • Canonical Notch signaling is activated in the stem or progenitor domain of gastrointestinal epithelium, such as basal layer in esophagus and lower part of the crypt in colon.
  • Notch signaling to inhibit secretory cell differentiation is oncogenic in gastric cancer and colorectal cancer, while Notch signaling to promote keratinocyte differentiation is anti-oncogenic in esophageal squamous cell carcinoma (SCC).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143535.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Notch
  • [Number-of-references] 60
  •  go-up   go-down


56. Aréchaga-Ocampo E, Pereira-Suárez AL, del Moral-Hernández O, Cedillo-Barrón L, Rodríguez-Sastre MA, Castillo-Alvarez A, López-Bayghen E, Villegas-Sepúlveda N: HPV+ cervical carcinomas and cell lines display altered expression of caspases. Gynecol Oncol; 2008 Jan;108(1):10-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HPV+ cervical carcinomas and cell lines display altered expression of caspases.
  • OBJECTIVE: Loss of expression of apoptotic regulatory proteins in many neoplasias might result in defective or delayed apoptosis, thus facilitating tumor growth or survival.
  • We analyzed here, the basal expression of precursors of apoptotic Caspases in normal cervical epithelium, HPV+ cervical tumor samples and HPV+ tumor-derived cell lines.
  • METHODS: Expression of initiator and effector Caspases was analyzed by immunochemistry in normal cervical epithelium and three types of cervical tumors (squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma) whereas expression of Caspases in HeLa, SiHa and CaSki cells was by immunofluorescence, Western blot and RT-PCR.
  • RESULTS: Expression of Caspases 3 and 9 was undetectable in adenocarcinoma and adenosquamous cell carcinoma, respectively.
  • Whereas in squamous cell carcinoma, the expression of Caspases was similar those observed in normal samples.
  • We did not observe an effect of the E6/E7 oncogenes on the expression of Caspases in C33-A cell.
  • CONCLUSION: Our results showed a differential expression of several Caspases in carcinoma samples and cell lines, suggesting multiple alterations of the Caspase pathways in cervical cancer.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / virology. Blotting, Western. Carcinoma, Adenosquamous / enzymology. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cell Line, Tumor. Female. Fluorescent Antibody Technique. HeLa Cells. Human papillomavirus 16. Human papillomavirus 18. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Paraffin Embedding. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936882.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.- / Caspases
  •  go-up   go-down


57. Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A: A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology; 2006;213(3):204-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Psoriasis is a chronic, incurable immune-mediated disease.
  • The results for the efalizumab-treated patients were compared with the data on psoriasis patients from insurance claims databases and a registry of events in the general population.
  • RESULTS: The efalizumab- and placebo-treated patients had similar incidence rates of malignancy, including lymphoproliferative disease, solid tumor, malignant melanoma and nonmelanoma skin cancer.
  • The incidence of nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma, in patients receiving efalizumab or placebo was elevated relative to the external databases.
  • The difference observed with nonmelanoma skin cancer may be due to biases introduced by the clinical trial methodology.
  • Additional patient observation is necessary to ascertain whether a link exists between efalizumab therapy and nonmelanoma skin cancer above that normally observed in psoriasis patients.

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033169.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Comparative Study; Meta-Analysis
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / efalizumab
  •  go-up   go-down


58. Eller MS, Asarch A, Gilchrest BA: Photoprotection in human skin--a multifaceted SOS response. Photochem Photobiol; 2008 Mar-Apr;84(2):339-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoprotection in human skin--a multifaceted SOS response.
  • Human skin has developed elaborate defense mechanisms for combating a wide variety of potentially damaging environmental factors; principal among these is UV light.
  • Despite these defenses, short-term damage may include painful sunburn and long-term UV damage results in both accelerated skin aging and skin cancers such as basal cell carcinoma, squamous cell carcinoma and even malignant melanoma.
  • The following sections briefly review UV-inducible protective responses in bacteria and in skin, thymidine dinucleotides (pTT) as a powerful probe of DNA damage responses, and potential means of harnessing these inducible responses therapeutically to reduce the now enormous burden of cutaneous photodamage in our society.
  • [MeSH-major] SOS Response (Genetics). Skin / radiation effects
  • [MeSH-minor] Animals. DNA Damage. Humans. Neoplasms, Radiation-Induced / genetics. Skin Neoplasms / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179622.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 10515
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 140
  •  go-up   go-down


59. Watanabe S, Sato K, Okazaki Y, Tonogi M, Tanaka Y, Yamane GY: Activation of PI3K-AKT pathway in oral epithelial dysplasia and early cancer of tongue. Bull Tokyo Dent Coll; 2009 Aug;50(3):125-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed genetic analysis using cDNA microarray and immunohistochemistry in 6 patients, 3 with precancerous lesions and 3 with early tongue cancer, to evaluate the usefulness of these methods in the diagnosis of precancerous lesions and early cancer.
  • Positive cells were noted in the basal and parabasal cell layers, and partially in the spinous layer of epithelial dysplasia tissues, and in the spinous layer of early cancer tissues.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Leukoplakia, Oral / metabolism. Phosphatidylinositol 3-Kinases / biosynthesis. Proto-Oncogene Proteins c-akt / metabolism. Tongue Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Early Detection of Cancer. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Male. Microdissection. Middle Aged. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Signal Transduction

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Tongue cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887755.001).
  • [ISSN] 0040-8891
  • [Journal-full-title] The Bulletin of Tokyo Dental College
  • [ISO-abbreviation] Bull. Tokyo Dent. Coll.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BCL2-related protein A1; 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


60. Jensen AØ, Thomsen HF, Engebjerg MC, Olesen AB, Friis S, Karagas MR, Sørensen HT: Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer; 2009 Jan 13;100(1):200-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study.
  • In North Jutland County, Denmark, we investigated whether use of oral glucocorticoids was associated with an increased risk of developing basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant melanoma (MM), and non-Hodgkin's lymphoma (NHL).
  • From the Danish Cancer Registry we identified 5422 BCC, 935 SCC, 983 MM, and 481 NHL cases during 1989-2003.
  • Prescriptions for oral glucocorticoids before diagnosis were obtained from the Prescription Database of North Jutland County on the basis of National Health Service data.
  • We found slightly elevated risk estimates for BCC (IRR, 1.15 (95% CI: 1.07-1.25)), SCC (IRR, 1.14 (95% CI: 0.94-1.39)), MM (IRR, 1.15 (95% CI: 0.94-1.41), and NHL (IRR, 1.11 (95% CI: 0.85-1.46)) among users of oral glucocorticoids.
  • Our study supports an overall association between glucocorticoid use and risk of BCC that cannot be explained by the presence of chronic diseases or concomitant use of other immunosuppressants.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Detect Prev. 2007;31(5):352-8 [18031945.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):692-701 [16508929.001]
  • [Cites] BMJ. 2008 Apr 12;336(7648):813-6 [18334527.001]
  • [Cites] Science. 2000 Mar 31;287(5462):2398-9 [10766613.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):683-6 [11531252.001]
  • [Cites] Transplant Proc. 2003 Aug;35(5):1714-6 [12962768.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):709-11 [15126608.001]
  • [Cites] J Natl Cancer Inst. 1988 Oct 5;80(15):1198-202 [3047407.001]
  • [Cites] Am J Epidemiol. 1992 May 1;135(9):1019-28 [1595688.001]
  • [Cites] J Autoimmun. 1992 Apr;5 Suppl A:363-71 [1503633.001]
  • [Cites] WHO Reg Publ Eur Ser. 1993;45:1-4 [8442841.001]
  • [Cites] Ann Epidemiol. 1993 Jan;3(1):111-2 [8287145.001]
  • [Cites] Ugeskr Laeger. 1996 Dec 9;158(50):7202 [9012031.001]
  • [Cites] Lancet. 1997 Feb 8;349(9049):398 [9033469.001]
  • [Cites] Dan Med Bull. 1997 Sep;44(4):445-8 [9377907.001]
  • [Cites] Dan Med Bull. 1997 Nov;44(5):535-9 [9408738.001]
  • [Cites] Am Fam Physician. 1998 Aug;58(2):443-50 [9713398.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):177-86 [10025742.001]
  • [Cites] Br J Dermatol. 1999 Feb;140(2):237-42 [10233215.001]
  • [Cites] Dan Med Bull. 1999 Jun;46(3):263-8 [10421985.001]
  • [Cites] Lancet. 1949 Dec 17;2(6590):1134 [15396965.001]
  • [Cites] Ann Rheum Dis. 2005 Dec;64(12):1765-8 [15843445.001]
  • [Cites] Int J Epidemiol. 2005 Dec;34(6):1370-6 [16172102.001]
  • [Cites] J Invest Dermatol. 2008 Apr;128(4):926-31 [17914446.001]
  • (PMID = 19034275.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / R01 CA57494
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids
  • [Other-IDs] NLM/ PMC2634665
  •  go-up   go-down


61. Ehrig T, Cockerell C, Piacquadio D, Dromgoole S: Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg; 2006 Oct;32(10):1261-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation.
  • The importance of the malignant potential of these lesions is well known.
  • RESULTS: Clinical diagnosis and histopathologic findings agreed in 91% (246/271) of the lesions biopsied.
  • (1) benign changes 4% (11/271) and (2) occult cutaneous malignancy in 5% (14/271) of the cases, 12 squamous cell carcinomas and 2 basal cell carcinomas.
  • CONCLUSIONS: In this study, about 1 in 25 clinically diagnosed AK lesions identified by board-certified dermatologist investigator(s) were occult early-stage squamous cell carcinomas on histologic assessment, a fact surmised by the medical community that until now had not been well quantified.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Disease Progression. Follow-Up Studies. Humans. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034376.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Kim JE, Kim HJ, Choi JM, Lee KH, Kim TY, Cho BK, Jung JY, Chung KY, Cho D, Park HJ: The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. Br J Dermatol; 2010 Nov;163(5):959-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma.
  • However, the effect of LL-37 against malignant skin cancer has not been reported.
  • OBJECTIVES: To investigate whether the human cathelicidin LL-37 is involved in the carcinogenesis of various skin tumours.
  • METHODS: Human cationic antimicrobial protein-18 (hCAP-18)/LL-37 production in several cell lines including HaCaT, a chronic myelogenous leukaemia (CML) cell line and various melanoma cell lines was examined using reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay.
  • Immunohistochemical analysis of melanoma, nonmelanoma skin cancer and precancerous and benign skin lesions was performed.
  • After adding LL-37 to a melanoma cell line, tumour cell proliferation, migration and invasion were investigated.
  • RESULTS: Human malignant melanoma cell lines overexpressed hCAP-18/LL-37 mRNA and peptide compared with HaCaT and CML cell lines.
  • Immunohistochemistry showed that the peptide was strongly expressed in malignant melanoma and moderately expressed in squamous cell carcinoma, whereas basal cell carcinoma, precancerous lesions and seborrhoeic keratosis showed no or weak expression.
  • LL-37 also stimulated melanoma cell proliferation, migration and invasion in vitro.
  • CONCLUSIONS: Cathelicidin LL-37 was primarily expressed in human malignant skin cancer.
  • LL-37 promoted melanoma cell proliferation, migration and invasion in vitro.
  • We report that an increase in the level of LL-37 is associated with malignant skin tumours such as malignant melanoma.
  • These results highlight the importance of LL-37 in the malignant tendency of skin tumours.
  • [MeSH-major] Antimicrobial Cationic Peptides / metabolism. Melanoma / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor / metabolism. Cell Movement / physiology. Cell Proliferation. Enzyme-Linked Immunosorbent Assay. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Precancerous Conditions / metabolism. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 20977442.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 143108-26-3 / CAP18 lipopolysaccharide-binding protein
  •  go-up   go-down


63. Bulliard JL, Panizzon RG, Levi F: [Epidemiology of epithelial skin cancers]. Rev Med Suisse; 2009 Apr 22;5(200):882, 884-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology of epithelial skin cancers].
  • [Transliterated title] Epidémiologie des cancers épithéliaux de la peau.
  • With no less than 15,000 estimated new cases diagnosed per year, non melanomatous carcinomas are the commonest cutaneous cancers in the Swiss population.
  • About 1 in 3 new cancer case is a basal (BCC) or a squamous cell carcinoma (SCC).
  • Incidence rates are steadily increasing, faster for BCC than SCC.
  • Systematic population-based registration of non melanomatous skin cancers faces many challenges that few cancer registries can meet.
  • However, detection of non melanomatous skin cancers benefits from these campaigns since prevention messages and means of early detection are similar for melanomas and other skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438088.001).
  • [ISSN] 1660-9379
  • [Journal-full-title] Revue médicale suisse
  • [ISO-abbreviation] Rev Med Suisse
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 31
  •  go-up   go-down


64. Danaee H, Karagas MR, Kelsey KT, Perry AE, Nelson HH: Allelic loss at Drosophila patched gene is highly prevalent in Basal and squamous cell carcinomas of the skin. J Invest Dermatol; 2006 May;126(5):1152-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic loss at Drosophila patched gene is highly prevalent in Basal and squamous cell carcinomas of the skin.
  • The human homolog of the Drosophila Patched gene (PTCH), located at chromosome 9q22.3, is frequently altered in both nevoid basal cell carcinoma syndrome, and sporadic basal cell carcinomas (BCCs).
  • However, alteration of the PTCH gene locus has been poorly studied in squamous cell carcinoma (SCC).
  • We found a high prevalence of any 9q22.3 LOH in both BCC (75.5%) and SCC (60.8%), with BCC being significantly more likely to have LOH than SCC (P<0.009).
  • The PTCH gene was specifically lost in 60% of BCC, and 50% of SCC tumors.
  • Thus, in our large, population-based sample, 9q22 loss, including PTCH, was highly prevalent in both BCC and SCC.
  • Overall, these data support the hypothesis that PTCH loss is a common, early lesion for SCC and BCC.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484983.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 82354; United States / NIEHS NIH HHS / ES / P42 ES 5947; United States / NIEHS NIH HHS / ES / ES 00002; United States / NIEHS NIH HHS / ES / P42 ES 07373; United States / NCI NIH HHS / CA / T32 CA 09078; United States / NCI NIH HHS / CA / CA 09078; United States / NCI NIH HHS / CA / CA 57494; United States / NCI NIH HHS / CA / R01 CA082354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


65. Neely D: Basal cell and squamous cell carcinoma in persons younger than 40 years. JAMA; 2006 Jan 18;295(3):278; author reply 279-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell and squamous cell carcinoma in persons younger than 40 years.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • (PMID = 16418458.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


66. Dixon A: Arc welding and the risk of cancer. Aust Fam Physician; 2007 Apr;36(4):255-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE STUDY: Mrs LF, 71 years of age, presents with numerous squamous cell carcinomas (SCCs) on her hands (Figure 1).
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Occupational Diseases / etiology. Skin Neoplasms / etiology. Welding

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392941.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


67. Hida Y, Kubo Y, Murao K, Arase S: Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res; 2007 May;299(2):103-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strong expression of a longevity-related protein, SIRT1, in Bowen's disease.
  • SIRT1 regulates cell survival via deacetylation of p53 and forkhead transcription factors, and overexpression of SIRT1 is reported to be essential for cell growth and survival in some kinds of cancer.
  • To elucidate the role of SIRT1 in human skin carcinogenesis, we have examined SIRT1 protein expression in 20 cases each of squamous cell carcinoma (SCC), basal cell carcinoma (BCC), Bowen's disease (BD), and actinic keratosis (AK) by immunohistochemical analysis.
  • Overexpression of SIRT1 is frequently observed in all kinds of non-melanoma skin cancers included in this study.
  • In addition, no obvious difference between AK and SCC was observed in the expression of SIRT1, suggesting that overexpression of SIRT1 may have some relevance to the early stage of skin carcinogenesis.
  • We suppose that SIRT1 could be one of the critical targets for future therapy with the aim of inhibiting cell proliferation and promoting apoptosis in non-melanoma skin cancers.
  • [MeSH-major] Bowen's Disease / metabolism. Sirtuins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Apoptosis / physiology. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Proliferation. Gene Expression Regulation, Neoplastic. Humans. Keratosis / metabolism. Keratosis / pathology. Sirtuin 1


68. Aoyagi S, Hata H, Homma E, Shimizu H: Controlling the histological margin for non-melanoma skin cancer conveniently using a double-bladed scalpel. J Surg Oncol; 2010 Feb 1;101(2):175-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controlling the histological margin for non-melanoma skin cancer conveniently using a double-bladed scalpel.
  • BACKGROUND: In some countries, intraoperative histological evaluation to control the surgical margin for non-melanoma skin cancer is widely used instead of Mohs micrographic surgery.
  • OBJECTIVES: To evaluate the efficacy of double-bladed scalpel for intraoperative histological margin control for non-melanoma skin cancers.
  • METHODS: Between 2005 and 2009, 10 basal cell carcinomas and 5 squamous cell carcinomas were underwent complete histological margin control in which a double-bladed scalpel was used during the surgery at the Hokkaido University Hospital in Japan.
  • RESULTS: The mean number of re-excisions required for complete tumor resection was 1.4 times.
  • The median time from the first tumor excision to reconstruction was 124 min.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082361.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Perrem K, Lynch A, Conneely M, Wahlberg H, Murphy G, Leader M, Kay E: The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths. Hum Pathol; 2007 Feb;38(2):351-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths.
  • The incidence and aggressiveness of nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma (SCC), in immunocompromised renal transplant recipients (RTRs) is dramatically higher (up to 100-fold) compared with the normal population.
  • SCC lesions are also predominant in RTRs, in contrast to the normal population where basal cell carcinoma is more common.
  • The mechanisms underlying this phenomenon are unknown, but effective treatments for these skin tumors would have a significant impact upon morbidity in this group of patients.
  • The fundamental role of telomeres and telomerase in the development of most human cancers, including melanoma, is well established, but very few reports have assessed their function during the onset of nonmelanoma skin cancer.
  • To assess whether telomere maintenance plays any role in the increased incidence of SCC in renal transplant patients, we analyzed both the telomere lengths and telomerase expression levels in 44 SCCs and 22 Bowen's disease (BD) samples (carcinoma in situ) from RTRs and nontransplant patients.
  • [MeSH-major] Bowen's Disease / etiology. Carcinoma, Squamous Cell / etiology. Kidney Transplantation / adverse effects. Skin Neoplasms / etiology. Telomere / genetics
  • [MeSH-minor] Base Sequence. Cell Line. HeLa Cells. Humans. Immunocompromised Host. Immunohistochemistry. In Situ Hybridization, Fluorescence / methods. Telomerase / biosynthesis


70. Farrell T, Chang YL: Basal cell adenocarcinoma of minor salivary glands. Arch Pathol Lab Med; 2007 Oct;131(10):1602-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of minor salivary glands.
  • Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.
  • The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.
  • Other diagnostic considerations include adenoid cystic carcinoma and basaloid squamous carcinoma.
  • Basal cell adenocarcinomas show strong immunoreactivity to cytokeratin 7 and variable myoepithelial staining with S100.
  • It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.
  • Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922602.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Ho T, Byrne PJ: Evaluation and initial management of the patient with facial skin cancer. Facial Plast Surg Clin North Am; 2009 Aug;17(3):301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation and initial management of the patient with facial skin cancer.
  • The incidence of skin cancer is on the rise, and facial plastic surgeons are frequently involved in its initial evaluation and management.
  • This article seeks to delineate the important information to be obtained during the history and physical examination of a patient presenting for facial lesion evaluation.
  • The biologic behavior and treatment options are summarized for the most commonly encountered skin cancers-basal cell carcinoma, squamous cell carcinoma, and melanoma.
  • [MeSH-major] Facial Neoplasms / pathology. Facial Neoplasms / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy, Needle. Carcinoma, Basal Cell / mortality. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cryosurgery / methods. Dermatologic Agents / therapeutic use. Female. Humans. Immunohistochemistry. Male. Melanoma / mortality. Melanoma / pathology. Melanoma / surgery. Mohs Surgery / methods. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Facial Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19698912.001).
  • [ISSN] 1558-1926
  • [Journal-full-title] Facial plastic surgery clinics of North America
  • [ISO-abbreviation] Facial Plast Surg Clin North Am
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Dermatologic Agents
  • [Number-of-references] 28
  •  go-up   go-down


72. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R: Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int; 2008 Nov;102(10):1369-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare and unusual histological variants of prostatic carcinoma: clinical significance.
  • We review the clinicopathological features of the following unusual histological variants of prostatic carcinoma: small cell carcinoma, ductal adenocarcinoma, sarcomatoid (carcinosarcoma), basal cell, squamous cell and adenosquamous, and urothelial carcinoma.
  • These variants are rare and account for 5-10% of carcinomas that originate in the prostate.
  • Only basal cell carcinoma is seen as a low-grade carcinoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Carcinosarcoma / pathology. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793296.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


73. Ezzedine K, Latreille J, Kesse-Guyot E, Galan P, Hercberg S, Guinot C, Malvy D: Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation. Eur J Cancer; 2010 Dec;46(18):3316-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation.
  • CONTEXT: In the SU.VI.MAX study, antioxidant supplementation for 7.5 years was found to increase skin cancer risk in women but not in men.
  • OBJECTIVE: To investigate the potential residual or delayed effect of antioxidant supplementation on skin cancer incidence after a 5-year post-intervention follow-up.
  • DESIGN, SETTING AND PARTICIPANTS: Assessment of skin cancer including melanoma and non-melanoma during the post-intervention follow-up (September 2002-August 2007).
  • MAIN OUTCOME MEASURES: Total skin cancer incidence, including melanoma, squamous cell carcinoma and basal cell carcinoma.
  • Six squamous cell carcinomas were found in women and 15 in men (10 and 25, respectively, for the total period).
  • Finally, 40 basal cell carcinomas appeared in women and 36 in men (98 and 94, respectively, for the total period).
  • No delayed effects, either on melanoma or non-melanoma skin cancers, were observed for either gender.
  • CONCLUSIONS: The risk of skin cancers associated with antioxidant intake declines following interruption of supplementation.
  • This supports a causative role for antioxidants in the evolution of skin cancers.
  • [MeSH-major] Antioxidants / adverse effects. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Vitamins / adverse effects

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20605091.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00272428
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Vitamins
  •  go-up   go-down


74. Heinen MM, Hughes MC, Ibiebele TI, Marks GC, Green AC, van der Pols JC: Intake of antioxidant nutrients and the risk of skin cancer. Eur J Cancer; 2007 Dec;43(18):2707-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intake of antioxidant nutrients and the risk of skin cancer.
  • To investigate the associations between intake of antioxidant nutrients and risk of basal cell (BCC) and squamous cell carcinomas (SCC) of the skin, we carried out a prospective study among 1001 randomly selected adults living in an Australian community.
  • Incident, histologically-confirmed BCC and SCC were recorded between 1996 and 2004.
  • High dietary intake of lutein and zeaxanthin was associated with a reduced incidence of SCC in persons who had a history of skin cancer at baseline (highest versus lowest tertile, multivariable adjusted relative risk (RR)=0.47, 95% confidence interval (CI): 0.25-0.89; P for trend=0.02).
  • In persons without a history of skin cancer at baseline, development of BCC was positively associated with intake of vitamins C and E from foods plus supplements (RR=3.1, 95% CI: 1.1-8.6; P for trend=0.03 and RR=2.6, 95% CI: 1.1-6.3; P for trend=0.02, respectively).
  • In those with a skin cancer history at baseline, dietary intake in the second tertile for beta-carotene (multivariable adjusted RR=2.2, 95% CI: 1.2-4.1) and for vitamin E (multivariable adjusted RR=2.1, 95% CI: 1.1-3.9) was associated with increased BCC risk, with no trend, and similar results were seen in those with a specific history of BCC.
  • These data suggest quite different associations between antioxidant intake and SCC compared with BCC, consistent with other evidence of their different causal pathways.
  • [MeSH-major] Antioxidants / administration & dosage. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology


75. Geist DE, Garcia-Moliner M, Fitzek MM, Cho H, Rogers GS: Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management. Dermatol Surg; 2008 Dec;34(12):1642-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management.
  • BACKGROUND: Perineural invasion (PNI) by cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) is an infrequent but not rare complication of traditionally low-morbidity skin cancers that can lead to catastrophic sequelae; 2.5% to 14% of CSCC and approximately 3% of BCC exhibit PNI.
  • MATERIALS AND METHODS: Cases of PNI treated with MMS and radiotherapy were reviewed for recurrence, disease-free follow-up, and adverse events.
  • When managing superficial skin tumors with PNI, a multidisciplinary team including a cutaneous surgeon and a radiation oncologist familiar with PNI is recommended.
  • [MeSH-major] Bell Palsy / etiology. Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / therapy. Skin Neoplasms / complications. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Mohs Surgery. Neoplasm Invasiveness. Peripheral Nerves

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bell's Palsy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018830.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Mazur PK, Grüner BM, Nakhai H, Sipos B, Zimber-Strobl U, Strobl LJ, Radtke F, Schmid RM, Siveke JT: Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine Kras(G12D)-induced skin carcinogenesis in vivo. PLoS One; 2010;5(10):e13578
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine Kras(G12D)-induced skin carcinogenesis in vivo.
  • To study the role of Notch and oncogenic Kras signaling in a progenitor cell population, Pdx1-Cre mice were utilized to generate conditional oncogenic Kras(G12D) mice with ablation of Notch1 and/or Notch2.
  • METHODOLOGY/PRINCIPAL FINDINGS: Surprisingly, mice with activated Kras(G12D) and Notch1 but not Notch2 ablation developed skin papillomas progressing to squamous cell carcinoma providing evidence for Pdx1 expression in the skin.
  • Immunostaining and lineage tracing experiments indicate that PDX1 is present predominantly in the suprabasal layers of the epidermis and rarely in the basal layer.
  • Further analysis revealed that loss of Notch1 but not Notch2 is critical for skin tumor development.
  • In addition, this finding may be relevant for research using Pdx1-Cre transgenic strains.
  • Additionally, our study confirms distinctive expression and functions of Notch1 and Notch2 in the skin supporting the importance of careful dissection of the contribution of individual Notch receptors.
  • [MeSH-major] Epidermis / metabolism. Genes, ras. Homeodomain Proteins / genetics. Receptor, Notch1 / physiology. Receptor, Notch2 / physiology. Skin / metabolism. Skin Neoplasms / genetics. Trans-Activators / genetics
  • [MeSH-minor] Animals. Base Sequence. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cells, Cultured. DNA Primers. Mice. Mice, Knockout. Papilloma / genetics. Papilloma / pathology. Reverse Transcriptase Polymerase Chain Reaction. beta Catenin / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genesis. 2000 Feb;26(2):143-4 [10686611.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13438-43 [20624967.001]
  • [Cites] Development. 2000 Jun;127(11):2421-32 [10804183.001]
  • [Cites] Genesis. 2000 Nov-Dec;28(3-4):147-55 [11105057.001]
  • [Cites] Nat Med. 2001 Mar;7(3):324-30 [11231631.001]
  • [Cites] Cell. 2001 May 18;105(4):533-45 [11371349.001]
  • [Cites] EMBO J. 2001 Jul 2;20(13):3427-36 [11432830.001]
  • [Cites] Clin Dermatol. 2001 May-Jun;19(3):244-52 [11479036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10863-8 [11517342.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):185-201 [11784003.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11225-32 [11781323.001]
  • [Cites] Development. 2002 May;129(10):2447-57 [11973276.001]
  • [Cites] Methods Cell Sci. 2001;23(4):189-96 [12486329.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):319-23 [12543782.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):416-21 [12590261.001]
  • [Cites] Diabetes. 2003 Dec;52(12):2896-904 [14633849.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):56-61 [14631368.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):375-87 [15093544.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):374-86 [15288263.001]
  • [Cites] Cell. 1980 Jan;19(1):245-54 [6153576.001]
  • [Cites] Mol Carcinog. 1993;7(2):99-110 [7681293.001]
  • [Cites] Nature. 1994 Oct 13;371(6498):606-9 [7935793.001]
  • [Cites] Development. 1996 Mar;122(3):983-95 [8631275.001]
  • [Cites] Mech Dev. 1996 Dec;60(2):175-84 [9025070.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7400-5 [9207103.001]
  • [Cites] Science. 1998 May 15;280(5366):1069-72 [9582119.001]
  • [Cites] Mech Dev. 1998 Nov;78(1-2):159-63 [9858718.001]
  • [Cites] J Biol Chem. 1999 Jan 8;274(2):1011-6 [9873045.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Nat Genet. 1999 Apr;21(4):410-3 [10192393.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Development. 1999 Aug;126(15):3415-24 [10393120.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):731-43 [15525534.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8804-7 [15604235.001]
  • [Cites] Differentiation. 2004 Oct;72(8):396-409 [15606499.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Dev Cell. 2005 May;8(5):665-76 [15866158.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Dev Biol. 2005 Aug 1;284(1):184-93 [15978571.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2024-9 [16882980.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Sep;7(9):678-89 [16921404.001]
  • [Cites] Genes Dev. 2006 Nov 1;20(21):3022-35 [17079689.001]
  • [Cites] J Exp Med. 2007 Feb 19;204(2):331-43 [17261636.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):266-79 [17785207.001]
  • [Cites] PLoS One. 2007;2(11):e1167 [18000539.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):544-55 [18242220.001]
  • [Cites] Dev Cell. 2008 Apr;14(4):594-604 [18410734.001]
  • [Cites] Development. 2008 Aug;135(16):2757-65 [18635610.001]
  • [Cites] Hepatology. 2008 Aug;48(2):607-16 [18666240.001]
  • [Cites] Oncogene. 2008 Sep 1;27(38):5115-23 [18758480.001]
  • [Cites] Cell. 2009 Apr 17;137(2):216-33 [19379690.001]
  • [Cites] Cancer Cell. 2009 Jul 7;16(1):55-66 [19573812.001]
  • [Cites] Nature. 2009 Nov 12;462(7270):182-8 [19907488.001]
  • [Cites] Mol Biol Cell. 2009 Nov;20(22):4838-44 [19793922.001]
  • [Cites] Nature. 2010 Apr 15;464(7291):1052-7 [20393564.001]
  • [Cites] Curr Biol. 2000 May 4;10(9):491-500 [10801437.001]
  • (PMID = 21042537.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Homeodomain Proteins; 0 / Notch1 protein, mouse; 0 / Notch2 protein, mouse; 0 / Receptor, Notch1; 0 / Receptor, Notch2; 0 / Trans-Activators; 0 / beta Catenin; 0 / pancreatic and duodenal homeobox 1 protein
  • [Other-IDs] NLM/ PMC2962652
  •  go-up   go-down


77. Stewart CJ: Tubulo-squamous vaginal polyp with basaloid epithelial differentiation. Int J Gynecol Pathol; 2009 Nov;28(6):563-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulo-squamous vaginal polyp with basaloid epithelial differentiation.
  • Tubulo-squamous polyp is a recently described and apparently benign lesion that most frequently involves the upper vagina of postmenopausal patients.
  • Histologically, it is characterized by the presence of cysts, squamous epithelial nests, and small tubular structures that are surrounded by a hypocellular fibrous stroma.
  • In this report, an additional case of tubulo-squamous polyp is presented in which there was prominent basaloid epithelial differentiation, mainly in the form of elongated cords of cells around the peripheral and deep aspect of the lesion.
  • This feature has not been recorded previously in tubulo-squamous polyp and potentially could create diagnostic difficulty with other lesions such as basal cell/adenoid basal carcinoma or small-cell neuroendocrine carcinoma.
  • [MeSH-minor] Aged. Cell Differentiation. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851205.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Mukoyama Y, Zhou S, Miyachi Y, Matsuyoshi N: T-cadherin negatively regulates the proliferation of cutaneous squamous carcinoma cells. J Invest Dermatol; 2005 Apr;124(4):833-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cadherin negatively regulates the proliferation of cutaneous squamous carcinoma cells.
  • T-cadherin is a unique member of the cadherin superfamily that lacks the transmembrane and cytoplasmic domains, and is instead linked to the cell membrane via a glycosyl-phosphatidylinositol anchor.
  • We previously reported that T-cadherin was specifically expressed on the basal keratinocytes of the epidermis, and the expression of T-cadherin was significantly reduced in invasive cutaneous squamous cell carcinoma (SCC) and in the lesional skin of psoriasis vulgaris.
  • In this study, to obtain an insight into the role of T-cadherin in keratinocytes, we used transfection methods and examined the effect of overexpression or knockdown of T-cadherin in immortalized keratinocyte cell lines derived from SCC.
  • T-cadherin overexpressed cells showed clearly reduced cell proliferation, but the influence of cell-cell adhesiveness and cell mobility was not detected.
  • Using a tetracycline-regulated expression system, we also confirmed that the suppression of cell proliferation was dependent on the expression level of T-cadherin.
  • Cell cycle analysis demonstrated that over expression of T-cadherin induced a delay in the G(2)/M phase.
  • [MeSH-major] Cadherins / physiology. Carcinoma, Squamous Cell / physiopathology. Skin Neoplasms / physiopathology
  • [MeSH-minor] Cell Aggregation / physiology. Cell Division / physiology. Cell Line, Tumor. Cell Movement / physiology. Down-Regulation. G2 Phase / physiology. Gene Expression. Humans. Keratinocytes / cytology. Keratinocytes / physiology


79. Johansen P, Berg K, Selbo PK, Hofbauer GF: [Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment of skin cancer]. Praxis (Bern 1994); 2010 Nov 17;99(23):1423-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment of skin cancer].
  • [Transliterated title] Photochemische Internalisierung (PCI): eine Weiterentwicklung der photodynamischen Therapie zur Behandlung von Hautkrebs.
  • Recently, several new and non-invasive methods have been introduced for the treatment of skin cancers.
  • Topical creams using the immune modulator imiquimod or the COX inhibitor diclofenac (with hyaluronic acid) are now registered for use against neoplasms such as basal or squamous cell carcinoma.
  • A refined version of PDT, namely photochemical internalisation, is currently subject to a first clinical trial in patients with osteosarcoma, squamous cell carcinoma, head and neck cancer as well as adenocarcinoma of the breast.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Melanoma / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Cytosol / drug effects. Endocytosis. Endosomes / drug effects. Humans. Melanoma, Experimental / drug therapy. Mice. Neoplasm Transplantation


80. Buell JF, Hanaway MJ, Thomas M, Alloway RR, Woodle ES: Skin cancer following transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc; 2005 Mar;37(2):962-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer following transplantation: the Israel Penn International Transplant Tumor Registry experience.
  • The purpose of this study was to analyze a large series of skin cancers in solid organ transplant recipients to determine their biologic behavior.
  • METHODS: A retrospective review of all US transplant recipients with skin cancer reported to the Israel Penn International Transplant Tumor Registry was performed.
  • RESULTS: Transplant recipients from the United States with skin malignancies were identified (n = 2018) and assigned to 1 of 3 groups: squamous cell cancer (SCC), basal cell cancer (BCC), or combined malignancies (BCC/SCC).
  • Squamous cell to basal cell cancer ratio was found to be 1.9 to 1.
  • The median interval from transplant to skin cancer diagnosis was greater than 4 years in each group and longest in those with isolated SCC lesions.
  • Cancer-specific deaths were significantly higher in the SCC (8%) and BCC/SCC (6.8%) groups compared to the BCC (3.6%) group.
  • CONCLUSIONS: This large experience indicates that SCC is more common than BCC in transplant recipients.
  • SCC alone or in combination with BCC appears aggressive and is associated with significant mortality.
  • [MeSH-major] Registries. Skin Neoplasms / epidemiology. Transplantation / adverse effects
  • [MeSH-minor] Carcinoma, Squamous Cell / epidemiology. Humans. Neoplasms, Basal Cell / epidemiology. Postoperative Complications / epidemiology. Recurrence. Retrospective Studies. Time Factors. United States / epidemiology


81. Farage MA, Miller KW, Berardesca E, Maibach HI: Neoplastic skin lesions in the elderly patient. Cutan Ocul Toxicol; 2008;27(3):213-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic skin lesions in the elderly patient.
  • The skin undergoes a lifetime of degenerative changes with the potential for genetic mutations occurring from exposure to solar radiation.
  • Malignant neoplasms, which can create significant morbidity, are increasing in parallel to an increase in prevalence.
  • Although public health measures emphasize prevention through limitation of exposures, the efficacy of sunscreen use is undocumented in the prevention of basal cell carcinoma and malignant melanoma.
  • [MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Keratosis, Actinic. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18988090.001).
  • [ISSN] 1556-9535
  • [Journal-full-title] Cutaneous and ocular toxicology
  • [ISO-abbreviation] Cutan Ocul Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Lipozencić J, Celić D, Strnad M, Toncić RJ, Pasić A, Rados J, Znaor A: Skin cancers in Croatia, 2003-2005: epidemiological study. Coll Antropol; 2010 Sep;34(3):865-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancers in Croatia, 2003-2005: epidemiological study.
  • This study presents the incidence of major nonmelanoma skin cancers (major NMSCs), other nonmelanoma skin cancers (other NMSCs) and malignant melanoma (MM) in Croatia.
  • The skin cancers recorded between 1 January 2003 and 31 December 2005 were retrospectively analyzed.
  • Incident cases of NMSCs were identified by the use of a questionnaire distributed to dermatology departments in Croatia and then collected at the University Department of Dermatology and Venereology, Zagreb University Hospital Center, and from the records kept at the National Cancer Registry.
  • Basal cell carcinoma (BCC) was the most common major NMSC in both sexes.
  • In the total number of major NMSCs, there were 7,244 cases of BCC.
  • Squamous cell carcinoma (SCC) was the second most common major NMSC.
  • The crude incidence rate was 54.9/100,000 for BCC in males, 53.9/100,000 in females, and 14.6/100,000 for SCC in male and 13.4/100,000 in female patients.
  • [MeSH-major] Skin Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Child. Child, Preschool. Croatia / epidemiology. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Melanoma / epidemiology. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20977074.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


83. Beljaards RC, Kirtschig G, Boorsma DM: Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma. Dermatol Surg; 2008 Nov;34(11):1577-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma.
  • [MeSH-major] Antigens, CD56 / biosynthesis. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798745.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


84. Bajpai U, Sharma R, Kausar T, Dattagupta S, Chattopadhayay TK, Ralhan R: Clinical significance of 14-3-3 zeta in human esophageal cancer. Int J Biol Markers; 2008 Oct-Dec;23(4):231-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently found 14-3-3 zeta to be overexpressed in esophageal squamous cell carcinomas (ESCCs) by differential display.
  • Matched distant histologically normal epithelia either showed basal cytoplasmic expression of 14-3-3 zeta or no detectable nuclear expression of the protein.
  • To our knowledge, this is the first report demonstrating overexpression of 14-3-3 zeta in esophageal hyperplasia, dysplasia and squamous cell carcinoma, suggesting that alteration in its expression occurs in early stages and is associated with esophageal tumorigenesis.
  • [MeSH-major] 14-3-3 Proteins / biosynthesis. Biomarkers, Tumor / biosynthesis. Carcinoma, Squamous Cell / metabolism. Esophageal Neoplasms / metabolism
  • [MeSH-minor] Adult. Cell Line, Tumor. Esophagus / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Hyperplasia / pathology. Immunoblotting. Male. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19199271.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


85. Filip A, Clichici S, Daicoviciu D, Adriana M, Postescu ID, Perde-Schrepler M, Olteanu D: Photochemoprevention of cutaneous neoplasia through natural products. Exp Oncol; 2009 Mar;31(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-melanoma skin cancers such as squamous cell carcinoma and basal cell carcinoma are the most common types of human tumors, representing 30% of the new cases of malignancies diagnosed each year.
  • Ultraviolet radiation (UV) from the sun is a major cause of non-melanoma skin cancer in humans.
  • Here we review the progress in the research of new and existing agents developed to protect the skin exposed to UV.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Cat's Claw. Flavonoids / therapeutic use. Phenols / therapeutic use. Phytotherapy. Polypodium. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300410.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Flavonoids; 0 / Phenols; 0 / Plant Preparations; 0 / Polyphenols; 0 / Silymarin; 4RKY41TBTF / silybin
  • [Number-of-references] 62
  •  go-up   go-down


86. Ishida M, Kushima R, Okabe H: Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol Rep; 2009 Oct;22(4):733-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin.
  • According to a previous study, beta III is not expressed in normal skin and squamous cell carcinoma.
  • However, its expression has not been examined in basal cell carcinoma (BCC) of the skin.
  • Expression of beta III was analyzed together with neural cell adhesion molecule (NCAM), chromogranin A, synaptophysin, epithelial membrane antigen (EMA) and cytokeratin (CK) 20 by immunohistochemical methods in 10 non-neoplastic skin tissues and 50 BCCs.
  • In the normal skin, immunoreactivity to beta III was restricted to the nerve bundles in the dermis and subcutis, no positivity was shown in epithelial cells of the epidermis and skin appendages. beta III and NCAM were expressed in 50 and 68% of BCCs, respectively, predominantly periphery of tumor nests, although the distribution of both markers was not always identical.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / metabolism. Skin Neoplasms / metabolism. Tubulin / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromogranin A / biosynthesis. Female. Hair Follicle / metabolism. Humans. Immunohistochemistry. Keratin-20 / biosynthesis. Male. Middle Aged. Mucin-1 / biosynthesis. Neural Cell Adhesion Molecules / biosynthesis. Synaptophysin / biosynthesis. Young Adult


87. Siddiqui F, Patel M, Khan M, McLean S, Dragovic J, Jin JY, Movsas B, Ryu S: Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1047-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Patients with pathologically proven malignant lesions in the head-and-neck region were treated using single-dose SBRT (S-SBRT) or fractionated SBRT (F-SBRT).
  • Pre- and post-SBRT tumor dimensions were measured in three axes, and tumor volumes were calculated.
  • The predominant histologic type was squamous cell carcinoma (n = 33).
  • Percentage of reduction in tumor volume was 52% +/- 38% based on follow-up scans in 24 patients.
  • Tumor control rates at 1 year were 83.3% and 60.6% in the primary and recurrent groups, respectively.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Esophagitis / etiology. Feasibility Studies. Female. Humans. Male. Middle Aged. Mucositis / etiology. Radiotherapy Dosage. Retreatment. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327895.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Ranganathan AC, Ojha S, Kourtidis A, Conklin DS, Aguirre-Ghiso JA: Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival. Cancer Res; 2008 May 1;68(9):3260-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival.
  • Pancreatic endoplasmic reticulum kinase (PERK)-eIF2 alpha signaling, a component of the endoplasmic reticulum (ER) stress response, has been proposed as a therapeutic target due to its importance to cell survival in hypoxic tumors.
  • In this study, we show that in addition to promoting survival, PERK can also suppress tumor growth of advanced carcinomas.
  • Our results show that in squamous carcinoma T-HEp3 cells, which display low PERK-eIF2 alpha signaling, inducible activation of an Fv2E-PERK fusion protein results in a strong G(0)-G(1) arrest in vitro.
  • Most importantly, Fv2E-PERK activation, in addition to promoting survival in vitro, inhibits T-HEp3 and SW620 colon carcinoma growth in vivo.
  • Increased PERK activation is linked to enhanced p-eIF2 alpha levels, translational repression, and a decrease in Ki67, pH 3, and cycD1/D3 levels, but not to changes in angiogenesis or apoptosis.
  • Experimental reduction of PERK activity, or overexpression of GADD34 in a spontaneously arising in vivo quiescent variant of HEp3 cells that displays strong basal PERK-eIF2 alpha activation, reverts their quiescent phenotype.
  • We conclude that the growth-inhibitory function of PERK is preserved in tumors and upon proper reactivation can severely inhibit tumor growth through induction of quiescence.
  • This is an important consideration in the development of PERK-based therapies, as its inhibition may facilitate the proliferation of slow-cycling or dormant tumor cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Sep;83(6):725-8 [10952775.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12625-30 [11035797.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):1011-22 [11381086.001]
  • [Cites] Rapid Commun Mass Spectrom. 2001;15(18):1693-700 [11555868.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1099-108 [11106749.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):619-33 [12667446.001]
  • [Cites] J Hepatol. 2003 May;38(5):605-14 [12713871.001]
  • [Cites] EMBO J. 2004 Jan 14;23(1):169-79 [14713949.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):2025-40 [14966282.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1906-10 [15026321.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7469-82 [15314157.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5943-7 [15342372.001]
  • [Cites] Oncogene. 1999 Nov 1;18(45):6112-20 [10557102.001]
  • [Cites] Mol Cell. 2000 May;5(5):897-904 [10882126.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7336-45 [15492254.001]
  • [Cites] Cell. 1983 Jun;33(2):323-33 [6407756.001]
  • [Cites] J Cell Biol. 1988 Dec;107(6 Pt 1):2437-45 [2848851.001]
  • [Cites] EMBO J. 1995 Aug 1;14(15):3828-34 [7641700.001]
  • [Cites] FASEB J. 1996 Oct;10(12):1378-87 [8903508.001]
  • [Cites] EMBO J. 1997 Dec 1;16(23):7207-16 [9384597.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8505-10 [10411905.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):89-104 [10508858.001]
  • [Cites] Semin Cell Dev Biol. 2005 Feb;16(1):3-12 [15659334.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2656-64 [16200199.001]
  • [Cites] EMBO J. 2005 Oct 5;24(19):3470-81 [16148948.001]
  • [Cites] Mol Cancer Res. 2005 Nov;3(11):597-605 [16317085.001]
  • [Cites] Neurology. 2006 Jan 24;66(2 Suppl 1):S102-9 [16432136.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1702-11 [16452230.001]
  • [Cites] Curr Mol Med. 2006 Feb;6(1):55-69 [16472113.001]
  • [Cites] Curr Opin Cell Biol. 2006 Aug;18(4):444-52 [16781856.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):723-8 [16861899.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):756-9 [16861911.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):729-35 [16861922.001]
  • [Cites] Nat Cell Biol. 2006 Oct;8(10):1053-63 [16964246.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(24):9517-32 [17030613.001]
  • [Cites] FEBS J. 2007 Feb;274(3):630-58 [17288551.001]
  • [Cites] Cancer Cell. 2007 Apr;11(4):349-60 [17418411.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3496-9 [17440054.001]
  • [Cites] PLoS One. 2007;2(7):e615 [17637831.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):834-46 [17957189.001]
  • [Cites] J Biol Chem. 2008 Jan 4;283(1):469-75 [17998206.001]
  • [Cites] J Pathol. 2000 Dec;192(4):446-54 [11113861.001]
  • (PMID = 18451152.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA117621-01; United States / NCI NIH HHS / CA / R01 CA109182-02; United States / NCI NIH HHS / CA / R01 CA109182-01A1; United States / NCI NIH HHS / CA / CA109182; United States / NCI NIH HHS / CA / R01 CA109182; United States / NCI NIH HHS / CA / R01 CA109182-04; United States / NCI NIH HHS / CA / F32 CA117621-03; United States / NCI NIH HHS / CA / F32 CA117621-01; United States / NCI NIH HHS / CA / CA117621-02; United States / NCI NIH HHS / CA / CA117621-03; United States / NCI NIH HHS / CA / F32 CA117621-02; United States / NCI NIH HHS / CA / R01 CA109182-03; United States / NCI NIH HHS / CA / F32 CA117621
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eukaryotic Initiation Factor-2; EC 2.7.10.- / PERK kinase; EC 2.7.11.1 / eIF-2 Kinase
  • [Other-IDs] NLM/ NIHMS42442; NLM/ PMC2587150
  •  go-up   go-down


89. Nieto Enriquez J, Medel Jiménez R, Huguet Redecilla P: Undiagnosed squamous cell carcinoma of the forehead presenting as a Tolosa-Hunt syndrome. Orbit; 2009;28(5):290-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undiagnosed squamous cell carcinoma of the forehead presenting as a Tolosa-Hunt syndrome.
  • Squamous cell carcinoma (SCC) is the second most common periocular skin cancer.
  • We describe a case of invasive squamous cell carcinoma arising from actinic keratosis and causing orbital and intracranial invasion via perineural spread.
  • Perineural invasion (PNI) is a known feature of SCC and very rarely basal cell carcinomas of the head and neck.
  • [MeSH-major] Brain Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Skin Neoplasms / diagnosis. Tolosa-Hunt Syndrome / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Fatal Outcome. Female. Forehead. Humans. Keratosis, Actinic / complications. Neoplasm Invasiveness


90. Ronen O, Malone JP, Kay P, Bivens C, Hall K, Paruchuri LP, Mo YY, Robbins KT, Ran S: Expression of a novel marker, Ubc9, in squamous cell carcinoma of the head and neck. Head Neck; 2009 Jul;31(7):845-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a novel marker, Ubc9, in squamous cell carcinoma of the head and neck.
  • The objective of this study was to determine the expression of Ubc9 in squamous cell carcinoma of the head and neck (SCCHN).
  • Ubc9 was significantly upregulated in the malignant and peritumoral tissues compared with mucosa from normal individuals.
  • In peritumoral tissues, Ubc9 expression was detected in the basal and suprabasal epithelial layers.
  • Tumor Ubc9 expression significantly correlated with clinical and pathologic stage.
  • These findings suggest that Ubc9 may play an important role in tumorigenesis and tumor progression of SCCHN.
  • [MeSH-major] Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / enzymology. Head and Neck Neoplasms / pathology. Ubiquitin-Conjugating Enzymes / metabolism
  • [MeSH-minor] Adult. Biomarkers / metabolism. Case-Control Studies. Female. Humans. Male. Middle Aged. Mucous Membrane / enzymology. Mucous Membrane / pathology. Neoplasm Invasiveness. Neoplasm Staging


91. Koh DM, Dzik-Jurasz A, O'Neill B, Tait D, Husband JE, Brown G: Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. Br J Radiol; 2008 Feb;81(962):91-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation.
  • The aim of this study was to evaluate the MR findings of anal carcinoma using an external pelvic phased-array coil before and after chemoradiation treatment.
  • 15 patients with carcinoma of the anal canal underwent T(2) weighted and short-tau inversion recovery (STIR) imaging before and after chemoradiation.
  • In 12 responders with long disease remission, a greater percentage reduction in the size of MR signal abnormality in the tumour area was observed at 6 months (mean 54.7%; 46-62%) than immediately after treatment (mean 38.6%; 30-46%) (p = 0.002, t-test).
  • Pelvic phased-array MR imaging is useful for local staging of anal carcinoma and assessing treatment response.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18238920.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


92. Gayre GS, Hybarger CP, Mannor G, Meecham W, Delfanti JB, Mizono GS, Guerry TL, Chien JS, Sooy CD, Anooshian R, Simonds R, Pietila KA, Smith DW, Dayhoff DA, Engman E, Lacy J: Outcomes of excision of 1750 eyelid and periocular skin basal cell and squamous cell carcinomas by modified en face frozen section margin-controlled technique. Int Ophthalmol Clin; 2009;49(4):97-110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of excision of 1750 eyelid and periocular skin basal cell and squamous cell carcinomas by modified en face frozen section margin-controlled technique.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Facial Neoplasms / surgery. Frozen Sections / methods. Skin Neoplasms / surgery. Surgical Procedures, Operative / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Incidence. Intraoperative Period. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Time Factors. Treatment Outcome. United States / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348860.001).
  • [ISSN] 1536-9617
  • [Journal-full-title] International ophthalmology clinics
  • [ISO-abbreviation] Int Ophthalmol Clin
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Muthusamy K, Halbert G, Roberts F: Immunohistochemical staining for adipophilin, perilipin and TIP47. J Clin Pathol; 2006 Nov;59(11):1166-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The presence of lipid in the cell cytoplasm is useful for supporting the diagnosis of sebaceous gland carcinoma (SGC).
  • The immunostaining was compared with 22 other eyelid tumours (11 basal cell carcinomas (BCC), 10 squamous cell carcinomas (SCC) and 1 Merkel cell tumour).
  • Anti-adipophilin was positive in five other eyelid tumours (4 BCC and 1 SCC) staining small cytoplasmic granules that can be easily distinguished from the staining in SGC.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Biomarkers, Tumor / analysis. Eyelid Neoplasms / diagnosis. Lipids / analysis. Sebaceous Gland Neoplasms / diagnosis
  • [MeSH-minor] Adipocytes / immunology. Antibodies, Monoclonal / immunology. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Carrier Proteins. DNA-Binding Proteins / analysis. Diagnosis, Differential. Humans. Intracellular Signaling Peptides and Proteins / analysis. Membrane Proteins. Paraffin Embedding. Peptides / analysis. Phosphoproteins / analysis. Pregnancy Proteins / analysis. Vesicular Transport Proteins

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Dermatopathol. 1999 Oct;21(5):426-31 [10535570.001]
  • [Cites] Surv Ophthalmol. 2005 Mar-Apr;50(2):103-22 [15749305.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):5101-8 [11084026.001]
  • [Cites] Dermatol Surg. 2002 Jul;28(7):623-31 [12135523.001]
  • [Cites] Eye (Lond). 2004 Jan;18(1):49-53 [14707966.001]
  • [Cites] Am J Dermatopathol. 2004 Aug;26(4):298-303 [15249860.001]
  • [Cites] Dermatol Surg. 2004 Aug;30(8):1164-8 [15274713.001]
  • [Cites] Trans Am Acad Ophthalmol Otolaryngol. 1968 Jul-Aug;72(4):619-42 [5706692.001]
  • [Cites] Int Ophthalmol Clin. 1982 Spring;22(1):23-61 [7061198.001]
  • [Cites] Hum Pathol. 1982 Feb;13(2):113-22 [7076199.001]
  • [Cites] Arch Ophthalmol. 1984 Feb;102(2):245-9 [6696670.001]
  • [Cites] Surv Ophthalmol. 1989 May-Jun;33(6):477-90 [2658172.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1985;1(1):35-42 [3940100.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1991;7(1):61-6 [2018750.001]
  • [Cites] Histopathology. 1993 Feb;22(2):127-33 [7681028.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):1-15; quiz 16-8 [7601925.001]
  • [Cites] J Lipid Res. 1995 Jun;36(6):1211-26 [7665999.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1998 Aug;236(8):561-6 [9717649.001]
  • [Cites] Cell Tissue Res. 1998 Nov;294(2):309-21 [9799447.001]
  • [Cites] Br J Ophthalmol. 1998 Sep;82(9):1049-55 [9893597.001]
  • [Cites] Eye (Lond). 1999;13 ( Pt 1):104-8 [10396393.001]
  • [Cites] Ophthalmology. 2004 Dec;111(12):2151-7 [15582067.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):639-42 [11299819.001]
  • (PMID = 16556662.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Lipids; 0 / Membrane Proteins; 0 / PLIN3 protein, human; 0 / Peptides; 0 / Phosphoproteins; 0 / Pregnancy Proteins; 0 / Vesicular Transport Proteins; 0 / perilipin 1; 0 / perilipin 2
  • [Other-IDs] NLM/ PMC1860497
  •  go-up   go-down


94. Prayaga AK, Loya AC, Gottimukkala SR, Digumarti RR, Maddali LS, Challa S: Cytologic features of primary malignant tumors of skin and adnexae. Acta Cytol; 2008 Nov-Dec;52(6):702-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of primary malignant tumors of skin and adnexae.
  • STUDY DESIGN: Cases of primary malignant tumors of skin and adnexae diagnosed on cytology with histopathology confirmation were retrieved from case records of 1998-2005.
  • RESULTS: Thirty primary malignant tumors of skin and adnexae were analyzed.
  • Melanoma was the most common (n=12), followed by squamous cell carcinoma (SCC) (n=5).
  • There were 3 basal cell carcinomas and 2 cases each of sebaceous carcinoma, Paget's disease of the breast and lymphoma.
  • There were single cases of eccrine carcinoma, malignant trichilemmal tumor, undifferentiated carcinoma and extramedullary myeloid cell tumor.
  • CONCLUSION: Cytodiagnosis of primary malignant tumors of skin and adnexae is possible based on morphology and clinical presentation.
  • [MeSH-major] Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Sebaceous / pathology. Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Cytodiagnosis. Humans. Lymphatic Metastasis. Medical Records. Melanoma / pathology. Paget's Disease, Mammary / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068675.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Asplund A, Gustafsson AC, Wikonkal NM, Sela A, Leffell DJ, Kidd K, Lundeberg J, Brash DE, Pontén F: PTCH codon 1315 polymorphism and risk for nonmelanoma skin cancer. Br J Dermatol; 2005 May;152(5):868-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTCH codon 1315 polymorphism and risk for nonmelanoma skin cancer.
  • BACKGROUND: The PTCH tumour suppressor gene is involved in the development of nearly all basal cell carcinomas (BCCs) of the skin and a fraction of squamous cell carcinomas (SCCs).
  • A nonconservative Pro/Leu nucleotide polymorphism within PTCH exon 23 at codon 1315 was recently reported to be potentially important for the development of breast epithelial cell cancers.
  • Objectives Accordingly, the status of PTCH codon 1315 was analysed for a possible association with the development of nonmelanoma skin cancers (NMSCs) in a pilot study.
  • Because skin cancer risk is affected by specific population-dependent phenotypes such as skin and hair colour, codon 1315 was also analysed for normal allele frequency variation in human populations having differing extents of eumelanin vs. phaeomelanin.
  • In 260 samples from 180 Swedish patients with NMSC and a control group of 96 healthy ethnically matched volunteers, no statistically significant pairwise differences between groups were detected in the PTCH codon 1315 allelic distribution, neither was a difference seen for multiple or early onset cases of BCC in the Swedish population.
  • In Swedish patients with single tumours, allelic loss (loss of heterozygosity) was observed in 20 of 30 (67%) patients with BCC and four of 22 (18%) patients with SCC, with no preference in the allele lost.
  • CONCLUSIONS: Our results indicate an association between the eumelanin-to-phaeomelanin shift and a shift from the Pro/Pro genotype to Leu-containing genotypes.
  • Failure to lose Pro during the shift to phaeomelanin may be associated with an increased population risk for BCC and increased individual risk for multiple BCC.
  • During development of a tumour, the effect of Pro may be magnified by loss of the Leu allele.
  • [MeSH-major] Genetic Predisposition to Disease. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide. Receptors, Cell Surface / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Codon / genetics. Genotype. Hair Color / genetics. Humans. Loss of Heterozygosity. Pilot Projects. Polymerase Chain Reaction / methods. Skin Pigmentation / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888139.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


96. Kaminagakura E, Bonan PR, Lopes MA, Almeida OP: Cell proliferation and p53 expression in pseudoepitheliomatous hyperplasia of oral paracoccidioidomycosis. Mycoses; 2006 Sep;49(5):393-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation and p53 expression in pseudoepitheliomatous hyperplasia of oral paracoccidioidomycosis.
  • Ki67 positive cells were present in the basal and parabasal layers in NOM and PEH, while in ED it was also observed in the spinous layer.
  • Percentage of ki67 positive cells was 7.7, 28.2 and 46.0 in NOM, PEH and ED respectively. p53 was negative in NOM and in PEH it was expressed by few cells in the basal layer of only three cases.
  • However, it was expressed in all cases of ED, in basal and parabasal layers.
  • Although histologically PEH mimics well-differentiated squamous cell carcinoma, its proliferative pattern and p53 expression are more similar to NOM than to dysplasia.
  • [MeSH-major] Hyperplasia / pathology. Mouth Diseases / metabolism. Mouth Diseases / pathology. Paracoccidioidomycosis / metabolism. Paracoccidioidomycosis / pathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Cell Count. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Epithelium / metabolism. Epithelium / pathology. Female. Humans. Immunohistochemistry. Inflammation / pathology. Ki-67 Antigen / metabolism. Male. Middle Aged

  • Genetic Alliance. consumer health - Paracoccidioidomycosis.
  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922791.001).
  • [ISSN] 0933-7407
  • [Journal-full-title] Mycoses
  • [ISO-abbreviation] Mycoses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


97. Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I: Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer; 2009;9:262
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.
  • BACKGROUND: Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea form lesions) are therapeutically challenging because they require considerable tissue loss and may demand radical disfiguring surgery.
  • The aim of this work was to evaluate the effect of a formulation containing IFNs-alpha and -gamma in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).
  • METHODS: Patients with extensive, recurrent, resistant to other procedures BCC or SCSC received the IFN formulation peri- and intralesionally, three times per week for 3 weeks.
  • Thirteen weeks after the end of treatment, the original lesion sites were examined for histological evidence of remaining tumor.
  • They beared 12 BCC and 4 SCSC ranging from 1.5 to 12.5 cm in the longest dimension.
  • At the end of treatment 47% CR (complete tumor elimination), 40% PR (>30% tumor reduction), and 13% stable disease were obtained.
  • CONCLUSION: The peri- and intralesional combination of IFNs-alpha and -gamma was safe and showed effect for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC in elder patients.
  • This is the first report of such treatment in patients with advance non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Interferons / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Bayes Theorem. Drug Resistance, Neoplasm. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Prospective Studies. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2726-34 [10537335.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] Science. 2000 Jun 30;288(5475):2357-60 [10875919.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2001 Jan;239(1):35-40 [11271459.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34 [11900988.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):933-7 [12072058.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jun;22(6):719-28 [12162884.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1485-95 [12368221.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] Acta Ophthalmol Scand. 2002 Dec;80(6):674-5 [12485296.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10):1027-34 [12974699.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):116-20 [14692941.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402 [15197337.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):342-6 [2405109.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1105-11 [2108862.001]
  • [Cites] Int Ophthalmol. 1990 Jul;14(4):285-94 [2370130.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(5):321-4 [2115817.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1637-49 [2120392.001]
  • [Cites] J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694-700 [2229497.001]
  • [Cites] Arch Dermatol. 1990 Dec;126(12):1660 [2256701.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9 [1869642.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):65-9 [1619079.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Ann Ophthalmol. 1993 Jan;25(1):11-3 [8427483.001]
  • [Cites] Drug Saf. 1994 Feb;10(2):115-50 [7516663.001]
  • [Cites] J Am Acad Dermatol. 1994 Nov;31(5 Pt 2):916-20 [7962748.001]
  • [Cites] Drugs. 1995 Jul;50(1):48-61 [7588089.001]
  • [Cites] Chin Med Sci J. 2007 Mar;22(1):38-43 [17441316.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1974-8 [17513803.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):889-92 [17638733.001]
  • [Cites] J Immunother. 2008 Jan;31(1):28-33 [18157009.001]
  • [Cites] Acta Pol Pharm. 2008 May-Jun;65(3):345-51 [18646554.001]
  • [Cites] J Immunother. 2008 Sep;31(7):599-606 [18600184.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):205-13 [18849299.001]
  • [Cites] Br J Nurs. 2009 Mar 26-Apr 8;18(6):346, 348-50 [19329898.001]
  • [Cites] Cancer Detect Prev. 1997;21(2):191-5 [9101080.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2691-6 [9389732.001]
  • [Cites] Dermatol Clin. 1998 Apr;16(2):377-98 [9589211.001]
  • [Cites] Acta Oncol. 1999;38(5):613-7 [10427950.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1849-57 [15547726.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 May;131(5):300-4 [15619125.001]
  • [Cites] Ophthalmology. 2005 Apr;112(4):717-23 [15808267.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2937-46 [15837745.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):217-22 [10605014.001]
  • (PMID = 19643007.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9008-11-1 / Interferons
  • [Other-IDs] NLM/ PMC2724551
  •  go-up   go-down


98. Wang GQ, Abnet CC, Shen Q, Lewin KJ, Sun XD, Roth MJ, Qiao YL, Mark SD, Dong ZW, Taylor PR, Dawsey SM: Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut; 2005 Feb;54(2):187-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population.
  • BACKGROUND: Oesophageal squamous cell carcinoma (OSCC) has a very poor prognosis, which is largely due to late diagnosis.
  • After adjusting for potential confounding factors, relative risks (95% confidence intervals) for incidence of this tumour, by initial histological diagnosis, were: normal 1.0 (reference), oesophagitis 0.8 (0.2-3.2), basal cell hyperplasia 1.9 (0.8-4.5), mild dysplasia 2.9 (1.6-5.2), moderate dysplasia 9.8 (5.3-18.3), severe dysplasia 28.3 (15.3-52.3), and carcinoma in situ 34.4 (16.6-71.4).
  • CONCLUSIONS: In this study, squamous dysplasia and carcinoma in situ were the only histological lesions associated with a significantly increased risk of developing OSCC within 13.5 years after endoscopy.
  • The follow up experience of severe dysplasia and carcinoma in situ was equivalent, suggesting that this distinction is not clinically relevant.
  • Documenting these precursor lesions of OSCC should assist in the development of effective prevention, early detection, and treatment strategies for this disease.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1984 Jul;15(7):660-9 [6745909.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Lancet. 1979 Aug 4;2(8136):217-21 [89331.001]
  • [Cites] Lancet. 1982 Apr 17;1(8277):876-9 [6122101.001]
  • [Cites] Int J Cancer. 1984 Nov 15;34(5):599-602 [6500739.001]
  • [Cites] Scand J Gastroenterol. 1986 May;21(4):392-8 [3726448.001]
  • [Cites] Endoscopy. 1987 May;19(3):91-5 [3608927.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):551-7 [3390795.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Jan-Feb;2(1):71-8 [8420615.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):185-8 [8486421.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92 [8360931.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1492-8 [8360932.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2027-37 [8156507.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):167-72 [8049639.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1686-92 [8082069.001]
  • [Cites] Ann Epidemiol. 1993 Nov;3(6):577-85 [7921303.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):121-30 [9037563.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):220-31 [9669803.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):226-33 [11158192.001]
  • (PMID = 15647178.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 263-MQ-731789; United States / PHS HHS / / 263-MQ-822420; United States / NCI NIH HHS / CP / N01-CP-40540; United States / NCI NIH HHS / SC / N01-SC-91030
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1774842
  •  go-up   go-down


99. Karagas MR, Stukel TA, Umland V, Tsoukas MM, Mott LA, Sorensen HT, Jensen AO, Nelson HH, Spencer SK, Perry AE, Stern RS: Reported use of photosensitizing medications and basal cell and squamous cell carcinoma of the skin: results of a population-based case-control study. J Invest Dermatol; 2007 Dec;127(12):2901-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reported use of photosensitizing medications and basal cell and squamous cell carcinoma of the skin: results of a population-based case-control study.


100. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA: Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res; 2006 Aug 1;66(15):7589-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis.
  • p63, a homologue of the tumor suppressor p53, is critical for the development and maintenance of squamous epithelia. p63 is specifically expressed in the basal layers of stratified epithelial tissues and is considered a specific marker for cells of this type.
  • Numerous studies have highlighted the oncogenic potential of the predominant p63 isoform DeltaNp63alpha; however, data suggest that other p63 proteins can act as tumor suppressors or alter the metastatic potential of tumors.
  • Disruption of p63 in squamous cell lines resulted in down-regulation of transcripts specifically expressed in squamous tissues and a significant alteration of keratinocyte differentiation.
  • Interestingly, we found that disruption of p63 led to up-regulation of markers of nonepithelial tissues (mesenchyme and neural tissue) in both primary and immortalized squamous cells.
  • Furthermore, loss of p63 expression was accompanied by a shift toward mesenchymal morphology and an increase in motility in primary keratinocytes and squamous cell lines.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Cell Movement / physiology. DNA-Binding Proteins / deficiency. Trans-Activators / deficiency. Tumor Suppressor Proteins / deficiency
  • [MeSH-minor] Cell Differentiation / genetics. Cell Differentiation / physiology. Cell Line, Tumor. Epithelium / metabolism. Epithelium / pathology. Epithelium / physiology. Humans. Keratinocytes / pathology. Mesoderm / metabolism. Mesoderm / pathology. Mesoderm / physiology. Neoplasm Invasiveness. Neoplasm Metastasis. Transcription Factors. Transfection. Up-Regulation

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885358.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 009385; United States / NCI NIH HHS / CA / CA 105436; United States / NCI NIH HHS / CA / CA 68485; United States / NCI NIH HHS / CA / CA 70856; United States / NIEHS NIH HHS / ES / ES 00267; United States / NIGMS NIH HHS / GM / GM 073407
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down






Advertisement